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FTO gene was the first gene that provided the strongest direct link to obesity 
uncovered by genome-wide association studies. Functional FTO is crucial for normal 
growth and development. Later on, FTO was identified as an m6A demethylase. M6A 
modification was known to be a prevalent mark across all kingdoms of organisms. In 
mammals, m6A occurred within a consensus sequence and was initially believed to be 
a permanent post-transcription modification in RNA. The ability of FTO to reverse 
m6A methylation prompted revisitation on the role of m6A in RNA transcripts. The 
status of m6A in RNA transcripts are further dynamically regulated by 
methyltransferases and m6A-binding proteins. This affects RNA splicing, translation 
and degradation, representing epigenetic regulation at the RNA level. FTO and 
ALKBH5 belonging to the AlkB 2OG oxygenases family are the only m6A 
demethylases known so far. They are implicated in unrelated diseases such as obesity 
for FTO and spermatogenesis for ALKBH5, revealing very different biological roles. 
It is not clear how FTO is selectively expressed over ALKBH5 and how FTO regulate 
the RNA methylation status in vivo. Thus, the mechanistic and structural studies of 
FTO will aid in the elucidation of FTO roles and functions. 
We developed and reported the first potent, selective and cell-active inhibitor for FTO 
through a combined approach of X-ray crystallography, differential scanning 
fluorimetry (DSF) and biochemical assays. Human AlkB oxygenases have conserved 
2OG-binding site but not substrate-binding site. This is supported by DSF which 
revealed m3T substrate only preferentially binds to FTO. Encouraged by this, we 
envisioned that selectivity and potency could be achieved by exploiting the substrate-
binding site. The inhibitor we have developed has at least 30-fold selectivity over 
other human AlkB oxygenases. Particularly, the inhibitor demonstrated a 100-fold 
 viii 
preference for FTO (IC50 = 0.81 μM, Tm shift = 11.2⁰C) over ALKBH5 (IC50 = 108.1 
PM; Tm = 2.7°C). The co-crystal structure of FTO complexed to inhibitor solved at 
atomic resolution revealed the basis of selectivity. The position of the pyridyl nitrogen 
of the inhibitor and Glu234FTO is crucial for the selectivity. This is important as we 
can potentially, selectively perturb FTO in cells. We further validated that the cell-
activity of the inhibitor. Potentially, this inhibitor can serve as a functional probe for 
mechanistic studies of FTO in cells.  
Next, we asked what determined the substrate specificity of FTO. Through in vitro 
demethylation studies, we concluded that FTO does not need m6A-containing 
consensus sequence for activity. Various secondary structural conformations are 
adopted by mRNA. Although m6A do not prevent duplex formation, the methylation 
was found to destabilise Watson-Crick base pairing by 0.5-1.7 kcal/mol depending on 
sequential context. We purposefully designed various m6A-containing RNA 
oligonucleotides that are highly similar in sequences that were able to form duplexes 
or hairpins in vitro. We showed that FTO and ALKBH5 are able to selectively 
demethylate m6A-containing hairpins. Demethylation caused a conformational 
change of the corresponding RNA oligonucleotides, adopting a duplex conformation. 
With this validation, it is fair to ask whether FTO performs its biological role by 
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1.1 Nonheme-Fe(II)/2-oxoglutarate (2OG)-dependent dioxygenases 
1.1.1 Overview  
Oxygenases that utilise ferrous iron are prevalent in nature and are utilised by 
organisms carrying out aerobic activities [1, 2]. Oxygenases are enzymes that use 
atmospheric diatomic oxygen and incorporate one or two oxygen atoms into the 
substrates. Monooxygenases, which incorporate one oxygen atom into their substrates, 
are arguably the first major class of oxygenases to be characterised and studied. An 
example is cytochrome P450, widely found in mammals, plants, insects, yeast and 
bacteria, oxidises a variety of functional groups through ferrous diatomic oxygen 
complex in the heme prosthetic group.  
Nonheme dioxygenases represent another class of oxygenases that perform oxidation 
by incorporating both atoms of diatomic oxygen into their substrates [3]. Nonheme-
Fe(II)/2-oxoglutarate (2OG)-dependent dioxygenases are a superfamily of oxidising 
enzymes utilised by nature and are found in organisms including mammals, plants and 
bacteria (Fig.1) [4-10]. Just like cytochrome P450, 2OG oxygenases are able to 
perform a variety of oxidation reactions on a wide range of substrates. The first 2OG 
oxygenase, collagen proline hydroxylase, was discovered in 1967 by Hutton et al. 
despite its prevalence in nature [11]. Prior to the report by Hutton et al., it was 
thought that hydroxyproline of collagen was incorporated by hydroxyproline amino 
acid [12]. With the advancement of genome sequencing technology, more 2OG 
oxygenases were identified in diverse organisms. In addition, the biological functions 




The α,β-heterodimeric hypoxia-inducible transcription factor (HIF) binds to various 
target genes upon exposure to low ambient oxygen environment, inducing responses 
to counter the anaerobic environment [13-16]. Prolyl hydroxylase domain-containing 
proteins (PHDs) are 2OG oxygenases and play a key role in hypoxic response. PHD 
hydrolyses the proline residues 402 and 564 of HIFα and therefore marks HIF for 
degradation via the ubiquitin-proteosome pathway. PHD acts as direct oxygen sensor, 
whereby in an ambient oxygen environment, HIF is not needed and thus degraded. 
Another family of human 2OG oxygenases (about 30 subfamily members) are the 
human jumoji domain-containing (JmjC)-type 2OG oxygenases [13, 14, 17, 18]. Most 
JmjC oxygenases are known to play a role in epigenetic regulation by oxidising 
Figure 1. Phylogenetic tree of human 2OG oxygenases. Despite low sequence 
identity, human ALKBH1-8, FTO and TET1-3 share highly similar structural 
elements and conserved residues. (Picture adapted from 'The roles of Jumonji-type 
oxygenases in human disease' [10].) 
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methylated lysine and arginine residues of histones. Histones modification via 
methylation is able to affect the chromatin structure and thus affect downstream gene 
expression [18, 19]. As such, JmjC oxygenases are of interest in cancer therapeutics. 
The ten eleven translocation (TET) family of proteins is composed of 3 known 
subfamily members of human 2OG oxygenases [14, 20, 21]. Tet has a smaller scope 
of substrate specificity and is only known to oxidise 5-methylcytosine and its 
derivative of DNA and RNA [22]. The Tet family proteins are believed to play an 
epigenetic role in embryonic stem cell pluripotency and cancer.  
The last major family of human 2OG oxygenases is the AlkB family of proteins [14, 
23-25]. This family consists of 9 subfamily members (Fig. 1). Some of the subfamily 
members are well characterised and they are known to play diverse biological roles, 
for instance, cancer, fertility and obesity. AlkB family of proteins can oxidise a range 
of methylated DNA and RNA nucleotides. Fat mass and obesity-associated protein 
(FTO), an obesity related protein, is one member of the AlkB subfamily [26]. The 
structural and mechanistic study of substrate recognition by FTO is the major subject 








1.1.2 The double-stranded β-helix (DSBH) domain 
The double-stranded β-helix (DSBH) fold is a characteristic structural feature of 2OG 
oxygenases (Fig. 2) [27-29]. DSBH fold is synonymous with JmjC, jelly-roll and 
cupin fold, these alternative names were derived from different communities of 
scientists. The DSBH core possesses an asymmetrical barrel-like structure, with one 
end of the barrel bigger than the other. The structure is made up of eight β-strands 
forming a pair of four-stranded antiparallel β-sheets. The antiparallel β-sheets are 
sometimes numbered in Roman numerals, from I to VIII and further classified into 
major and minor β-sheets. The major β-sheet generally has longer amino acid chains 
consisting of β-strands I, VIII, III and VI, whereas the minor β-sheet has shorter 
amino acid chains consisting of β-strands II, VII, IV and V.  
It is common to observe the presence of α-helixes preceding the DSBH fold of 2OG-
oxygenases. The α-helixes are generally situated on the exterior of the DSBH core 
and are believed to contribute to the stability of DSBH. In addition, β-strands at the 
N-terminal of DSBH fold could participate in substrate selection and binding. Within 
the DSBH fold, loops and short helical inserts connect between β-strands. Particularly, 
the βIV/V insert that is located between β-strand IV and V displays 2OG-oxygenases 
subfamily dependent characteristics. Note that βIV/V inserts vary in length, and play 
various roles among 2OG oxygenases such as acting as dimerisation interface and 
substrate interaction (Fig. 2B) [30-32]. For instance, the βIV/V insert of mammalian 
TET2 DSBH contains 379 amino acids and is highly disordered [33]. It is situated at 
the exterior of the DSBH fold surface and does not affect the demethylation activity 
of TET2. The precise function of the βIV/V insert of mammalian TET2 remains 
unknown. On the other hand, the βIV/V insert of PHD2, a subfamily member of PHD 




 Figure 2. The double-stranded β-helix (DSBH) domain. A. Crystal structure depicting the typical DSBH jelly-roll motif made up of eight β-strands. B. 2D 
topology diagram for 2OG oxygenases. (Picture is adapted from 'Structural studies 
on human 2-oxoglutarate dependent oxygenases' [28].) 
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The crystal structures of 2OG oxygenases solved so far ubiquitously showed that the 
catalytic sites are located at the bigger opening end of the DSBH fold, where the 
substrates approach the 2OG oxygenases [4, 27-29]. Co-factor and co-substrate, 
ferrous iron and 2-oxoglutarate respectively, are located in the catalytic site [34]. The 
ferrous iron is coordinated by the iron binding amino acid motif, a HxD/E...H triad (x 
being any amino acid residue), which is generally conserved across the 2OG  
oxygenases family (Fig. 3) [35, 36]. The histidine is located at the end of β-strand II 
and an aspartate or glutamate residue is resided one amino acid away in the loop that 
connects the β-strands II and III. The second ferrous iron binding histidine is located 
at the start of the β-strand VII. The characteristic fold of the DSBH is such that the 
triad of amino acid residues are brought in close proximity, ligand to the ferrous iron 
metal center, forming one side of a triangular face of the octahedron.  
Co-substrate 2OG coordinates to the ferrous iron in a bidentate manner through the 1-
carboxylate and 2-oxo groups. The 1-carboxylate is observed to be trans to either one 
of the histidine residues while the 2-oxo group is trans to the aspartate or glutamate 
residue in the available crystal structures. However, for some 2OG oxygenases that 
perform halogenation, the aspartate or glutamate residue proved not to be crucial for 
catalysis [37, 38]. The 5-carboxylate group of 2OG that points towards the smaller 
opening end of the DSBH fold interacts via electrostatic and hydrogen bonding with 
basic residues, such as a lysine (for JmjC family) located at the start of β-strand IV, or 
an arginine (for PHD and AlkB family) located at the start of β-strand VIII [39, 40]. 
The 5-carboxylate group is further stabilised by an alcoholic residue from the 
surrounding such as serine/threonine or a tyrosine, further enriching the hydrogen 








Figure 3. Structure-based sequence alignment of AlkB oxygenases. Alignment 
depicting the DSBH domains of various crystallised AlkB oxygenases. The eight 
β-strands (βI-VIII) that made up the DSBH domains are relatively conserved, 
making up of similar amino acids except for βIV. Only FTO has a L1 loop 
(highlighted green). The amino acids between βIII and βIV are disordered for FTO 
(underlined in red) and absent in other homologs. All AlkB oxygenases shown 
here have short βIV/V inserts (5-12 amino acids in length). Columns marked with 
asterisk (*) depict conserved residues that bind to 2OG. Catalytic triad HxD…H 
are involved in chelation to Fe(II) while arginine is involved in hydrogen bonding 
to the 5-carboxylate group of 2OG  The alignment was performed by T-coffee and 
the diagram was prepared by ESPript 3.0 [35, 36]. 
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 1.1.3 Catalytic cycle 
Presence of diatomic oxygen is essential for the catalysis of 2OG dioxygenases [27-29, 
41]. At the start of the catalytic cycle, the ferrous iron is at the rest state, where it is 
ligand to the HxD/E...H triad motif with three water molecules trans to each of the 
amino acid, forming a octahedral coordination geometry (Fig. 4). Co-substrate 2OG 
then comes in and displaces two water molecules (step 1). Co-crystallised structures 
of 2OG oxygenases with 2OG or N-oxalylglycine (NOG) are often observed in this 
conformation whereby the metal centre is hexa-coordinated by the triad motif, the 
bidentate coordination of 2OG or NOG and water molecule [31-33, 39, 42]. The water 
molecule is displaced by diatomic oxygen upon the onset of the catalytic reaction 
(step2). 
The 2OG oxygenase superfamily is able to oxidise a wide range of substrates [8, 9, 11, 
22, 23, 43, 44]. The proposed consensus catalytic mechanism that is discussed below 
is for N-methylated substrates that have direct relevance to this thesis [45-47]. 
Binding of diatomic oxygen leads to the formation of superoxo radical anion (O2-) 
coordinating to the oxidised Fe(III). The anionic diatomic oxygen then performs a 
nucleophilic attack at the α-carbon of 2-oxo group of 2OG forming a bridged peroxo 
intermediate (step 3). After which, decarboxylation occurs and two oxygen atoms 
from the diatomic oxygen are each incorporated into the succinate by-product and 
Fe(IV)-oxo intermediate (step 5). Upon formation of Fe(IV)-oxo intermediate, the 
oxygen is brought close to the substrate for hydroxylation (step 6). The hydroxylation 
of substrate occurs through a radical formation mechanism whereby Fe(III) is reduced 
to Fe(II) with eventual incorporation of a hydroxyl group onto the substrate (step 7). 
Spontaneous deformylation occurs giving the demethylated substrate (step 8). 
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Succinate leaves the ferrous iron allowing the incorporation of co-substrates for 












Figure 4. Catalytic cycle for N-demethylation. (Modified from 'Nucleic acid 
oxidation in DNA damage repair and epigenetics' [41].) 
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1.2 Types of substrates for AlkB family of 2OG oxygenases 
1.2.1 Alkylated nucleobases due to oxidative damage 
Genomic DNA in cells is exposed to various environmental alkylating factors that 
non-enzymatically introduce methylations or exocyclic adducts, which are cytotoxic 
[48-51]. Alkylating agents can be classified into SN2 and SN1 types.  Commonly 
known SN2 agents include methylmethane sulphonate (MMS) and methyl halides, 
which come from combusted biomass, cigarette smoke and industrial by-products. On 
the other hand, SN1 agents include nitroso-compounds like N-methyl-N-nitrosourea, 
which come from reaction of nature occurring nitrite with decaying food and waste 
matters. Methylation by methyl radicals could also occur due to environmental factors.  
Across the four classical bases in DNA, there are twelve possible sites for methylation, 
which include exocyclic oxygen and nitrogen and the endocyclic nitrogen (Fig. 5) 
[50]. In addition, the oxygen atom of negatively charged phosphate backbone of DNA 
is also susceptible to methylation. When the DNA bases are base paired, the oxygen 
and nitrogen from the nucleobases are protected from alkylation damage agents. Thus, 
it is believed that alkylation damages occur during transcription and translation, when 
ssDNA is present due to unwinding of the DNA helix.  
Hydrogen bonding between complementary nucleobases in Watson-Crick base 
pairings can be disrupted if the hydrogen bond acceptors, which consist of a lone pair 
of electrons, are unavailable due to alkylation such as methylation. The inability of 
DNA to form proper base pairing will inevitably result in the normal functions of the 
cells leading to cytotoxicity [49]. Alkylated nucleobases happen to be the substrates 
of AlkB family of 2OG-oxygenases [52, 53]. Cells utilise the AlkB family of 2OG-
 12 
oxygenases to reverse the effect of methylation damage on their DNA and RNA. A 















Figure 5. Twelve possible sites for alkylation damage. Atoms marked with 
green arrows reflect sites of that are susceptible to methylation damage. 
Alkylations at certain heteroatoms prevent duplex formation thus toxic to cells. 
(Modified from ‘Repairing DNA-methylation damage' [50].) 
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1.2.2 Methylation due to purposed addition 
Purposed chemical modifications that directly affect transcription or translation of 
DNA and RNA, respectively, or indirectly via histones modifications, provide an 
additional layer of control for downstream biological functions [54, 55]. The term 
'epigenetics' is coined for the regulation of genetic expression through dynamic 









Figure 6. Methylation marks. Purposeful methylations involved in epigenetic 
regulation can be found in histones, DNA and RNA. (Modified from ‘The 
control of histone lysine methylation in epigenetic regulation' [58].) 
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1.2.3 Methylated histones 
A well-studied example is the covalent modifications by a variety of chemical 
functional groups on amino acids located at the N-terminal tails of the histones (Fig. 6) 
[18, 56-58]. Well-documented chemical modifications on histones tail include 
methylation, acetylation and phosphorylation. Common amino acid residues that are 
subjected to chemical modifications are lysine, arginine, threonine and serine. Those 
chemical modifications are dynamic as they can be covalently added and removed 
enzymatically. Acetyl functional groups are added and removed by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) respectively. On the 
other hand, methylation are added and removed by histone methyltransferases (HMTs) 
and (JmjC)-type 2OG oxygenases respectively. The presence of chemical 
modifications affects the packaging of DNA in the chromatin, asserting an effect on 











1.2.4 Methylated nucleobase of DNA  
DNA methylation, catalysed by DNA methyltransferases [59], is known to play roles 
in genomic imprinting, X chromosome inactivation, embryogenesis and cancer in 
mammalian cells. Interestingly, DNA methylation was first known to only exist as 5-
methylcytosine (5mC) in animals, plants and fungi [60]. 5mC occurs in the CpG 
islands, which are regions in the genome with repeating cluster of cytosine and 
guanine (Fig. 6) [55, 61-64]. Methylated CpG consists of about 1% of the entire DNA 
bases in the genome and they are mostly found methylated in a symmetrical manner 
together with their complementary counterpart. Approximately 60% of the human 
gene is believed to be regulated by promoters associated with CpG islands. 5-
hydroxymethylcytosine (5hmC), the oxidised form of 5mC, was also reported to be a 
stable epigenetic mark of cytosine [65-67]. It was of great interest as 5mC was 
thought to be the only epigenetic modification. 5hmC was found to link to the 
maintenance of mammalian embryonic stem cells (ESCs) state. Further reports 
confirmed the role of 5hmC in playing a part in the differentiation potential of 
pluripotent ESCs through epigenetic reprogramming.  
TET1 was the first member of the TET family to be identified as the 2OG oxygenase 
that oxidises the substrate 5mC to its product 5hmC, this finding has implicated the 
involvement of TET1 in epigenetic reprogramming of ESCs [65, 68]. TET2 and TET3 
were subsequently reported to be able to perform a similar oxidation reaction [69]. 
5hmC is further oxidised by the TET family of proteins to 5-formylcytosine (5fmC) 
and finally to 5-carboxylcytosine (5caC) [70-72]. 5fmC and 5caC are stable 
modification products that are also involved in ESCs state maintenance.  
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Mammalian N6-methyladenosine (m6A) in DNA was recently reported to be present 
in ESCs and is involved in epigenetic regulation by preventing the expression of 
genes [73]. M6A in DNA is a substrate of ALKBH1, a member of AlkB family of 
2OG oxygenase.  
1.2.5 Methylated nucleobase (m6A) of RNA  
N6-methyladenosine (m6A) is the most prevalent form of methylated nucleobase in 
mammalian RNA, with an average of three m6A modifications per mRNA (Fig. 6) 
[74-76]. It is believed that m6A was first identified in mRNA of isolated mammalian 
cell lines in 1974 [77, 78]. Desrosier et al. reported that m6A was exclusively found 
in mRNA and not in any other RNA types such as ribosomal RNA. Subsequently, 
m6A was also identified in RNA of viruses, plants and yeasts [79-82]. M6A was 
initially believed to be a permanent post transcription modification by a 
methyltransferase and remain unaltered for the rest of the mRNA short half-life [83, 
84]. In 2014, it was established that the methylation in the N6 position of adenosine in 
human cells is regulated by human methyltransferase-like 14 (METTL14) and 
METTL3 [85]. The METTL3-METTL14 heterodimer complex is regulated by Wilm's 
tumor 1-associating protein (WTAP) that localises the heterodimer complex to the 
nuclear speckles, where the target mRNA is located [86]. Earlier this year, structural 
and biochemical studies revealed that METTL3 contained the active domain for 
methylation while METTL14 structurally stabilised METTL3 for efficient catalysis, 





Demethylation of m6A: Research on the function of mammalian m6A progressed 
slowly, and it was reignited when the N6-methylation mark was found to be removed 
by a member of the AlkB 2OG oxygenase family, FTO, in 2011 (Fig. 7) [26, 43]. The 
activity of FTO towards m6A is confined to a single stranded oligonucleotide, with 
almost negligible activity towards a duplex oligonucleotide. Prior to this discovery, 
FTO was thought to be a 3-methylthymine (3-meT) (for ssDNA) and 3-methyluricil 
(3-meU) (for ssRNA) demethylase [90, 91]. This is of huge significance as it shows 
that the N6-methylation can be dynamically regulated, potentially playing a role 
similar to that of 5mC of the CpG island. Furthermore, in 2013, ALKBH5, a member 
of the AlkB 2OG oxygenase family was reported to be able to demethylate m6A, 
sharing a same substrate as FTO [44, 92]. Like FTO, ALKBH5 is only active towards 
single stranded oligonucleotides. However, FTO and ALKBH5 perform oxidative 
demethylation through different mechanisms [93]. Oxidative demethylation of FTO 
goes through two oxidative derivatives of m6A. They are namely N6-
hydroxymethyladenosine (hm6A) and N6-formyladenosine (f6A), both are stable 
species with half-life of about 3 hours. They resemble the oxidised derivatives of 5mC, 
namely 5hmC and 5fmC respectively. Despite resembling the cytosine counterparts, 
the exact biological significance of hm6A and f6A is unknown. In contrast, the 
presence of hm6A and f6A was not observed for the oxidative demethylation of 
ALKBH5. This might be due to the difference between structural alignment of the 
residues in FTO and ALKBH5 active domain, thus suggesting the different ways of 









Consensus sequence: M6A methylation marks RNA in a non-random manner and is 
almost exclusively found within a set of consensus sequence motif, DR(m6A)CH 
(where D = A, G or U; R = G or A and H = A, C or U) (Fig. 8) [74, 94-96]. M6A is 
unevenly distributed along a RNA transcript with increasing prevalence near the stop 
codon and 3' untranslated region (3' UTR) (Fig. 8A). The elucidation of the motif was 
largely benefitted by the advancement of high throughput sequencing, bioinformatics 
analysis software packages and specificity of m6A antibodies (Fig. 8B and C) [97, 98]. 
The general strategy undertook was fragmentation of mRNA, followed by 
immunoprecipitation of m6A-containing RNA and finally, sequencing. Nevertheless, 
credit also must be given to pioneers whom reported m6A mostly occurring in 
G(m6A)C and A(m6A)C motifs, shedding light on non-random distribution of m6A 
[99, 100]. Not all consensus motifs will be methylated at the same time in RNA 
transcripts. This represents the dynamic nature of m6A modifications.  
Figure 7. Oxidative demethylation of m6A. Black arrows represent the reaction 
pathway taken by both FTO and ALKBH5. Red arrows represent the reaction pathway 
that can be taken only by FTO. (Adapted and modified from ‘FTO-mediated formation 












Figure 8. M6A profiling in RNA transcript. A. Prevalence of m6A in the stop 
codon region in a RNA transcript. B. Key steps in m6A-immunoprecipitation 
sequencing. C. Sequence motifs containing m6A peaks. Size of nucleotide represents 
frequency of reads. (Adapted and modified from ‘Gene expression regulation 
mediated through reversible m6A RNA methylation’ [96], ‘The dynamic 
epitranscriptome: N6-methyladenosine and gene expression control’ [75] and 
‘Transcriptome-wide mapping of N6-methyladenosine by m6A-seq based on 
immunocapturing and massively parallel sequencing.’ [94]) 
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M6A regulating proteins: M6A is found in various types of RNAs such as mRNA, 
microRNA (miRNA) and long noncoding RNA (lncRNA) [101-105]. M6A in RNA is 
found to affect mRNA splicing, stability, translation and localisation [106-109]. This 
represents an additional layer of epigenetic regulation via covalent modification of 
RNAs. For instance, m6A in mRNA can directly affect and determine cell fate of 
ESCs and pre-adipocytes [110-116]. The position of m6A found in mature mRNA 
affects downstream biological activities. M6A in 5' UTR is involved in translation and 
localisation upon binding by eukaryotic initiation factor 3 (eIF3) complex or 
YTHDF2 respectively [112, 117]. M6A in the 3' UTR regulates translation and 
mRNA stability by the binding of YTH family of proteins [106, 117]. Human YTH 
family of proteins (YTHDF 1-3 and YTHDC 1 and 2) has high affinity (nM range) 
towards the methylated consensus motif [106, 108, 118-120]. Different members of 
the YTH family can bind to m6A in different parts of mRNA affecting different 
downstream biological consequences. As such, methylation in the N6 position of 
adenosine (by METTL3-METTL14 complex) resulted in m6A, which can be 
demethylated (by FTO or ALKBH5) and recognised (by eIF3 or YTH domains). Thus, 

















Figure 9. Writer, eraser and reader proteins of m6A in human.  M6A is 
dynamically regulated in RNA transcripts. (Modified from ‘Update: Mechanisms 
underlying methyladenosine modification of eukaryotic mRNA.’ [128]) 
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Duplex involving m6A: RNA oligonucleotides are able to form duplexes via Watson-
Crick base pairing [129]. The presence of a methyl group on the N6 of the adenine 
nucleobase does not prevent m6A from the formation of Watson-Crick base pairing 
with its uracil counterpart [130]. However, the presence of a single methylation can 
destabilise the RNA duplex by approximately 1.4 kcalmol-1 [131]. The destabilisation 
occurs as the methyl group is forced to rotate, leading to adopting a high-energy anti 
conformation. It is also reported that the amount of destabilisation is dependent on 
sequential context [132]. In living system, dynamic modification of m6A can affect 
RNA duplex structure (close hairpin to an open hairpin) (Fig. 10). An example will be 
the RNA binding protein, heterogeneous nuclear ribonucleoprotein C (HNRNPC), 
which asserts a downstream biological effect upon binding [104, 105, 133]. This is 






Figure 10. M6A-switch mechanism. The presence of m6A enhanced binding of 
HNRNPC. Demethylation of m6A caused a structural change to the hairpin and 
disfavoured association of HNRNPC. (Adapted from ‘N6-methyladenosine-
dependent RNA structural switches regulate RNA-protein interaction.’ [104]) 
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1.3 Human fat mass and obesity-associated protein (FTO) 
1.3.1 FTO and obesity 
Arguably, FTO is the most well-studied and characterised member in the human AlkB 
family at the genetic and protein level [134-142]. FTO is the first genome-wide 
association studies (GWAS) identified gene that has direct implication in obesity. 
FTO gene is located on chromosome 16 and is more than 400 kilobase long. Previous 
attempts to link obesity to genetic basis proved to be futile before the GWAS. Three 
independent studies reported that various single nucleotide polymorphisms (SNPs) 
have a positive correlation to body mass index (BMI), a common indicator for obesity 
[143-145]. Individuals homozygous for each risk allele SNP contributes to about 3 kg 
and approximately 1.67-fold risk of being obese to an individual who does not possess 
the risk allele. Following the reports in 2007, many groups around the world reported 
that FTO gene SNPs indeed have significant association with obesity via BMI [146-
155]. Prior to the discovery of FTO as an obesity gene, studies of FTO were done and 
reported on mouse [156-159]. Heterozygous FTO deletion in mouse caused fused toes 
phenotype and homozygous FTO knockout cause malformation and mid-gestation 
death. There was no report on FTO effect on obesity and thinness. However the 
mouse models were not accurate models for the study of FTO as the mice lacked 
several important genes. FTO is reported to be only found in vertebrates and marine 




Physiological effects of FTO: As mentioned earlier in this thesis, FTO codes for a 
2OG oxygenase belonging to the AlkB family of proteins [26, 162]. However, the 
exact biology of FTO and action pathway that leads to obesity was not well known. 
Reports of FTO started to accumulate after the three landmark GWAS in 2007 in bid 
to elucidate the role of FTO in obesity [143-145]. Evidence pointed to mammalian 
FTO being expressed in various regions that has relations to energy expenditure 
regulation such as skeletal muscles and liver adipose tissue [163]. In addition, FTO 
mRNA is found in cerebellum, hippocampus and hypothalamus [164, 165]. Although 
FTO has direct link to obesity, it is noteworthy that FTO variants were also reported 
to be linked to acute coronary syndrome, elevated blood pressure and 
hyperandrogenemia in woman with polycystic ovary syndrome [166-168].  
Energy regulation by FTO: The first direct evidence how FTO affects obesity by 
energy haemostasis was observed when a FTO knockout mouse model displayed a 
lean body mass with significant reduction in fat mass via increasing energy 
expenditure [169]. In addition, FTO knockout mouse was observed to have relatively 
high postnatal mortality and if the mouse survived, exhibited growth retardation. This 
provided evidence that FTO might play a role more than just energy homeostatic that 
leads to obesity. The following year, 2010, it was reported that mice models with an 
additional knock-in of one and two FTO gene copies exhibited obesity due to 
increased fat mass from higher food intake [170]. The authors suggested that FTO 
induced obesity might be a due to FTO influenced hormonal leptin release through 
adipose tissues. With increasing evidence that FTO influences obesity by the 
propensity of food intake, some focus was turned to how and which part of the brain 
is affected by FTO expression level [160, 165, 171]. FTO expression level changes 
upon increase and decrease food deprivation. It is in the hypothalamus of the brain 
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where the expression of FTO seems to affect food intake preferences [172-175]. In the 
event of fasting, there is a 60% decrease of FTO mRNA level in the arcuate situated 
in the hypothalamus. Level of FTO in hypothalamus that affects food intake is also 
consistent with various reports by other groups. 
FTO demethylase and obesity: Some investigations were performed to probe the link 
between catalytic activity of FTO and obesity [176, 177]. One such investigation was 
performed on a mouse model, which had a point mutation (isoleucine to 
phenylalanine) at position 367 of FTO gene. The point mutation occurred in a 
conserved region of around 20 amino acids across vertebrates not in the catalytic 
domain. The mouse model exhibited reduced FTO expression with corresponding 
reduction in catalytic activity of FTO. The mouse models did not suffer growth 
retardation unlike their FTO knockout counterparts. However, the mouse models 
exhibited maturity onset reduction in fat mass and body weight. This indirectly 
reflects the influence of the catalytic activity of FTO to obesity. Reviews provided 
thus far are from animal models. There are little documented cases of how catalytic 
impairment of FTO affects human beings.  A loss-of-function mutation at position 
316 of human FTO where arginine was mutated to glutamine was reported in some 
members of a Palestinian Arab consanguineous family [177]. Arginine 316 is 
important for the binding of co-substrate 2OG. It is an autosomal recessive disease 
where affected members displayed post-natal growth retardation, dysmorphism of 
head and face, psychomotor malfunction, cardiac and genital functional defects. 
Incidentally, there is a recent report of a patient who had homozygous mutation of 
histidine 271 to proline that catalytically impaired FTO [178]. The patient suffered 
very much the same physiology. No obesity was reported in those affected members 
but it is evident that a functioning FTO plays a greater role than just obesity.  
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SNPs in FTO: Much research focus of FTO in affecting obesity has been placed in the 
relative expression level of the protein in animal models. Although evidences pointed 
to FTO expression level is indeed able to affect obesity, questions still remain on how 
the non-coding first intronic variants of the FTO gene are able to control the 
expression level of FTO and thus, affect obesity. In 2014, it was reported that the 
intronic variant of FTO acts as a long range enhancer for a neighbouring gene named 
Irx3 [141, 179]. The promoter of IRX3 interacts with the first intronic variant of FTO 
and regulates IRX3 expression. IRX3-deficient mice have reduced body weight up to 
30% with less fat mass and higher metabolism. This report offered direct evidence at 
molecular level of how the first intronic SNPs of FTO gene is linked to obesity. FTO 
expression level was reproducibly showed to affect obesity, however the authors did 
not address how IRX3 is able to affect expression of FTO. 
FTO and adipogenesis: In recent years, much attention was also turned to how FTO 
regulate the development of adipose tissues which causes obesity [113, 180, 181]. In 
2014, it was reported that FTO expression and the level of m6A in mouse 3T3-L1 pre-
adipocytes have inverse relationship during adipogenesis. Catalytically active FTO is 
able to promote adipogenesis through the regulation of m6A level. On the other hand, 
FTO knockdown is able to prevent differentiation of pre-adipocytes. FTO influences 
adipogenesis by affecting the expression of two isoforms of an adipogenesis 
regulating factor, Runt-related transcription factor 1 (RUNX1T1) through the control 
of the m6A level, which is positioned near the edge of an exon close to a splice site. 
In the absence of FTO, methylation near the splice site results in the recruitment of a 
protein named SRSF2, which induces exon inclusion and thus the expression of 
RUNX1T1 long isoform (RUNX1T1-L). RUNX1T1-L prevents differentiation of 
3T3-L1 pre-adipocytes. However, SRSF2 is not recruited in the absence of m6A near 
 27 
the splice site due to FTO demethylation. This causes exon skipping that results in the 
expression of RUNX1T1 short isoform (RUNX1T1-S). RUNX1T1-S promotes 
differentiation of 3T3-L1 pre-adipocytes. Subsequently, there are more reports 
supporting the role of FTO in regulating adipogenesis in adipocytes [182, 183]. 
However, there was no report on how the first intronic SNPs of FTO play in 
adipogenesis.  
There is also no information of the direct link of how the first intronic SNPs of FTO 
could affect FTO expression level. So far, obesity caused by the first intronic SNPs of 
FTO and the expression level of functional FTO are proved to be independent of each 
other. It remains to be elucidated whether any links on the molecular biology level 
could be drawn from the effect of intronic SNPS on FTO expression. 
1.3.2 Structural basis of substrate recognition by FTO 
The first crystal structure of FTO was reported in 2010 (Fig.11) [91]. FTO was 
recombinantly expressed in Escherichia coli (E.coli) and was crystallised with an N-
terminal nickel affinity tag containing six histidine residues followed by a thrombin 
cleavage site (amino acid residues: LVPRGS). The first 31 amino acid residues from 
the N-terminal of FTO were truncated for crystallisation. This was not surprising as 
about twenty residues from the N-terminal were predicted to be disordered through 
prediction using various servers [184, 185]. Despite the truncation, crystal structure of 
FTO allowed us to study the DSBH domain, characteristic of AlkB 2OG oxygenase 
family and the C-terminal helical bundle domain in great details. 
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Structural features of FTO: Like many 2OG oxygenases, β-strands and α-helixes 
precedes the DSBH domain in FTO. Two long α-helixes, α-helix 3 and α-helix 4 lie at 
the exterior of the DSBH domain, the side consisting of major β-sheets, presumably to 
provide structural integrity to the DSBH domain (Fig. 11). Two NRLs are located at 
the bigger opening end of the DSBH core domain, forming part of the entrance into 
the catalytic domain of FTO. NRL1 is longer, making up of about fifteen amino acid 
residues (Fig. 3). The tip of NRL1 comprises a short α-helix with five residues. Of the 
five residues, two of them are basic residues arginine and lysine, believed to interact 
with oligonucleotides. NRL2 is made up of two β-strands joined by a short loop 
containing two residues. L1 loop (17 amino acid residues), named by the authors, is 
located between β-strand I and II of the DSBH domain (Fig. 3 and 11). Notably, L1 
loop is unique and highly conserved among FTO proteins across different species, and 
it is absent in other AlkB proteins. Although it is highly unstructured, seemingly, the 
loop is rigidified by hydrophobic interaction between residues in L1 loop (Tyr220 and 
Phe221) and second β-strand (Trp230) of the DSBH domain (Fig. 12). In addition, 
Glu218 of L1 interacts with Trp230, conferring additional stability. This might be the 
reason why the electron density of L1 loop could be observed as it was predicted to 
have high conformational flexibility. Superimposition of AlkB:dsDNA (PDB ID 
4NID) and ALKBH2:dsDNA (PDB ID 3BUC)  complexes with FTO revealed a steric 
clash of the non-methylated strand with L1 loop (Fig. 13) Taken into consideration 
the rigidity of L1 loop, L1 loop may play a part in the substrate selection, preferring 
single-stranded oligonucleotides over duplexes. βIV/V insert of FTO is about seven 
residues long and do not appear to participate in any substrate selectivity event. 
Notably, L1 loop of FTO occupies an almost similar position as βIV/V insert of 
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hALKBH5. Thus, βIV/V insert of hALKBH5 is believed to be responsible for single-
stranded oligonucleotides selectivity [186].  
FTO has a characteristic C-terminal domain helical bundle. The C-terminal domain is 
made up of four main helixes and represents a new type of fold. Notably, C terminal 
domain is absence in the members of AlkB 2OG oxygenase family discussed in this 
thesis. The exact function of C-terminal domain helical bundle is unknown. However, 
the presence of the C-terminal domain is essential in maintaining the activity of the 
DSBH domain, presumably, through stabilisation. Co-expressed DSBH and the C-
terminal domain were able to form stable complexes in vitro, and subsequently, able 
to recover some of the lost enzymatic activity.  
Like other AlkB 2OG oxygenase family members, FTO has a highly conserved iron 
binding amino acid motif, a HxD/E...H triad. The first crystal structure of FTO (PDB 
ID: 3LFM) provided structural insights into substrate binding mechanism of FTO. 
The carboxylate group of NOG occupy deep into the 2OG binding domain, forming 
hydrogen bonding interaction with Arg316 (Fig. 14). The co-crystallised substrate 
m3T is tucked in between NRL2 and the 2OG binding domain. Tyr108 of NRL2 and 
His231 of the catalytic triad sandwiches the nucleobase ring of m3T through a slightly 
distorted π- π stacking interaction. The methyl group of m3T is situated just beside the 
co-factor iron(II), facilitating the hydroxylation reaction via the Fe(IV)-oxo 
intermediate. Furthermore, m3T is stabilised by the hydrogen bonding between the 
amide nitrogen of Glu234 and O4-m3T. M3T and NRL1 are unable to make 
meaningful interaction as they are not in close proximity. However, as NRL1 is 
placed nearer to the surface of FTO, it is believed to be able to interact with 
oligonucleotide substrate.  
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It is noteworthy that FTO has never been crystallised with ssRNA although it has 
been widely acclaimed that FTO is able to demethylate its natural substrate m6A 
found in RNA. Arguably, a cross-linking strategy must be used to observe the binding 
mechanism of FTO with oligonucleotides [43]. This will shed light on the exact role 
of L1 loop, NRL1, NRL2 and C-terminal domain helical bundle play in substrate 








Figure 11. Overall structure of FTO (PDB ID 3LFM). Characteristic 
structural features of FTO include L1 loop (purple) and the C-terminal helical 
bundle (red helices on the left of FTO). NRL 1 & 2 is indicated in the diagram as 
a pair of yellow hairpins situated between the helical bundle and the DSBH 
domain (cyan). Two long α-helixes, α-helix 3 and α-helix 4 lie at the exterior of 
the DSBH domain. M3T is situated near the opening of the catalytic domain, 
lying next to NRL2. NOG, analog of natural co-substrate 2OG is embedded in 









Figure 12. Hydrophobic interaction between L1 loop and DSBH of FTO. The 
loop is rigidified by hydrophobic interaction between residues (Tyr220 and 
Phe221) in L1 loop (purple) and βII (Trp230) of the DSBH domain. In addition, 
Glu218 of L1 interacts with Trp230, conferring additional stability. Figure adapted 
from PDB ID 3LFM. 
Figure 13. Steric clash of FTO L1 loop (purple) with dsDNA. A. Alignment of 
FTO (white) (PDB ID 3LFM) with AlkB:dsDNA (cyan) (PDB ID 4NID). B. 
















Figure 14. Catalytic domain of FTO with m3T and NOG. The carboxylate 
group of NOG occupy deep into the 2OG-binding domain, forming hydrogen 
bonding interaction with Arg316. Nucleobase of m3T is sandwiched between 
Tyr108 and His231. Figure adapted from PDB ID 3LFM. 
 33 
1.4 Other AlkB nucleic acid demethylases 
1.4.1 Escherichia coli (E.coli) AlkB 
AlkB protein from E.coli is arguable to be the first identified member of the AlkB 
2OG oxygenase family [187]. AlkB protects bacteria from oxidative alkylating 
damage [188, 189]. AlkB was identified in 1983 when Sekiguchi and co-workers 
discovered that E.coli with AlkB mutation sensitised E.coli to methylation agent 
methyl methanesulfonate (MMS). The subsequent reports revealed that AlkB 
expression is able to suppress alkylation damage of DNA in bacteria. In addition, 
AlkB introduced into mammalian cells reverse methylation damage to DNA [190, 
191]. However, its molecular mechanism was not known due to lacking biochemical 
data although there were some reports of AlkB being iron dependent and its substrates 
were DNA nucleobases [192]. In 2001, the mystery of AlkB function was revealed 
through sequence profiling analysis, namely a 2OG dependent oxygenase protein [8].   
Given the discovery of AlkB belonging to the 2OG dependent oxygenase superfamily, 
repair mechanisms of AlkB then started to emerged [193-196]. It was found that AlkB 
directly repair the cytotoxic damage on both single and double stranded DNAs by 
demethylating 1-methyladenosine (m1A) and 3-methylcytosine (m3C). Moreover, 
AlkB was found to have a range of substrates preference as it was later reported to be 
able to reverse methylation damage of nucleobases, 1-methylguanosine (m1G) and 
m3T in DNA and RNA. Arguably, AlkB represent the most promiscuous member of 
the AlkB family of 2OG oxygenases known so far [197-201].  
Crystal structures of AlkB revealed information regarding how NRL and βIV/V 
inserts accommodate a range of oligonucleotide substrates [39, 40, 202, 203]. AlkB 
was also solved with DNA duplex crosslinked via disulphide bond revealing 
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mechanism of DNA damage repair. AlkB from E.coli serves as a 'model' protein for 
the study of human AlkB family of 2OG oxygenases. AlkB facilitated our 
understanding of substrate recognition mechanism by AlkB family of 2OG 
oxygenases. In addition, AlkB was used as a proof-of-concept for the development of 
potent and selective inhibitors that discriminate other family 2OG oxygenases, paving 
way for functional probes and drug design for human AlkB family of 2OG 
oxygenases [204-207]. 
1.4.2 Human ALKBH1 (ALKBH1) 
ALKBH1 was identified in 1996, the first human AlkB family of oxygenases 
discovered, sharing high similarity (52%) with AlkB from E. coli [208]. However, the 
function of ALKBH1 in vivo is not as well characterised as its counterparts FTO and 
ALKBH5. In addition, the structure of ALKBH1 is not available, and it will be 
interesting to know how much the DSBH domain of ALKBH1 resembles that of AlkB 
from E.coli.  
ALKBH1 is believed to be a DNA demethylase as it is able to partially rescue the 
phenotype of E.coli with loss-of-function mutation of AlkB when exposed to 
alkylating agent MMS. However, the natural substrate of ALKBH1 is still under 
debate. The substrates of ALKBH1 are m3C, methylation marks on histone 2A and 
most recently, m6A in DNA [73, 209-212]. If the aforementioned methylated 
substrates were proved to be natural substrates, ALKBH1 could be the most 
promiscuous human AlkB 2OG oxygenase family member. It is noteworthy that m3C 
is the only oxidative damage caused lesion and the other two substrates are considered 
to be epigenetic marks. Several reports have pointed out that ALKBH1 could be more 
than an alkylated damage repair enzyme [209, 210, 212-214]. A few studies have 
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reported that ALKBH1 is a mitochondrial protein and play a crucial role in stem cells 
differentiation via epigenetic regulation. Those reports showed that ALKBH1 regulate 
transcription epigenetically via histones and DNA methylation. However, we cannot 
completely rule out a possible role of ALKBH1 in epigenetic regulation at RNA level 
as it does not discriminate ssDNA or ssRNA substrates [73]. 
1.4.3 Human ALKBH2 (ALKBH2) 
ALKBH2 was first discovered in 2002 as a DNA lesion repairing enzyme [215]. It 
was identified through analysing the sequence identity and secondary structure 
prediction, further validated by enzymatic assays. ALKBH2 is reported by various 
groups to demethylate m1A, m3T and m3C with a slight preference to act on dsDNA 
over ssDNA [50, 197, 198, 216-220]. The first crystal structure of ALKBH2 was 
solved with dsDNA cross-linked to the active domain and it represents the only one in 
complex with nucleic acids for the entire human AlkB family [40]. In the crystal 
structure of ALKBH2:dsDNA complex, notably 3 basic residues RKK (Arg241 to 
Lys243) interacted with  the negatively charged dsDNA and Phe102 finger residue 
maintains the π- π stacking interaction of the dsDNA duplex when the modified base 
of dsDNA is flipped out into the catalytic domain. The ALKBH2:dsDNA complex 
crystal structure gives a glimpse of the mechanism of how ALKBH2 binds and repairs 
dsDNA lesions. 
Like many other human AlkB oxygenase family members, biological function of 
ALKBH2 is not well characterised. ALKBH2 primarily act as DNA repair enzyme, 
which maintains cellular environment caused by alkylation damage thus preventing 
cell death [221]. Despite the perceived usefulness of ALKBH2, the presence of its 
active form is persistent in bladder cancers and glioblastoma [222-225]. Drugs used 
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during cancer therapy are often alkylating agents, damaging the genome of cancer 
cells leading to apoptosis. ALKBH2 often contributes to drug resistance in 
chemotherapy, which is probably caused by cancer cell taking advantage of the repair 
property of ALKBH2 that can reverse damaged DNA.  
1.4.4 Human ALKBH3 (ALKBH3) 
The first report of the characterisation of ALKBH3 as a DNA repair enzyme was 
made at about the same time as ALKBH2 with the similar types of experimental 
validations[215]. Similar to ALKBH2, ALKBH3 has very much diminished activity 
toward short oligonucleotides (trimer)[197]. Both ALKBH3 and ALKBH2 are able to 
demethylate similar nucleotide substrates. In contrast to ALKBH2, ALKBH3 is 
unable to demethylate dsDNA. The structural basis of why ALKBH3 does not act on 
dsDNA was elucidated through comparing crystal structure of ALKBH2:dsDNA 
complex and the crystal structure of ALKBH3 [42, 226, 227]. Glu123 of ALKBH3 
corresponds to Phe102 of ALKBH2 in the crystal structures. In the crystal structure of 
ALKBH2:dsDNA complex, Phe102 finger residue plays an important role by 
facilitating the maintenance of the structural integrity of dsDNA by π- π stacking 
interaction when ALKBH2 performs its enzymatic activity. However, Glu123 of 
ALKBH3 is negatively charged in nature, presumably, repelling the phosphate 
backbone of dsDNA, destabilising the formation of ALKBH3:dsDNA complex. In 
addition, when Glu123 of ALKBH3 was mutated to Phe123, ALKBH3 gained 
dsDNA demethylation property. This elucidated the substrate selectivity mechanism 
of ALKBH2 and ALKBH3. 
Compared to its ALKBH2 counterpart, biological roles and functions of ALKBH3 are 
better characterised. Particularly, ALKBH3 is also known as prostate cancer antigen-1 
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(pca-1) as it was first observed high expression level in prostate carcinoma samples 
[228-232]. ALKBH3 transfected cell lines displayed resistance against MMS-induced 
cell death, most probably through the dealkylation properties of ALKBH3. Other than 
prostate cancer, ALKBH3 is also implicated in non-small-cell-lung cancer, pancreatic 
cancer, papillary thyroid cancer and human rectal carcinoma [229, 233, 234]. The 
mechanism of how ALKBH3 maintains genome integrity via resistance to alkylation 
and thus continuous proliferation of various types of tumours and healthy cells was 
elucidated in 2011 [235]. In a pull down experiment, ALKBH3 was associated with 
activating signal cointegrator complex 3(ASCC3). ASCC3 was then determined to be 
a 3'-5' helicase that unwinds DNA, allowing the methylated base in a ssDNA to be 
repaired by ALKBH3. Due to overexpression and the hijacked of ALKBH3 for 
prostate cancers' own advantage, ALKBH3 serves as a viable therapeutic target. As 
such, efforts have been invested to develop a drug that targets ALKBH3. There is 
only one crystal structure of ALKBH3 complexed with NOG thus far and more 
crystal structures solved with small molecular inhibitors will facilitate the rational 
drug design target ALKBH3. 
1.4.5 Human ALKBH5 (ALKBH5) 
The first attempted characterisation of ALKBH5 as a human AlkB 2OG oxygenase 
was in 2011 [92]. Despite testing a range of known methylated substrates for human 
AlkB family of 2OG oxygenases, the authors failed to identify a suitable substrate for 
recombinant ALKBH5. Finally, characterisation of ALKBH5 as an AlkB family of 
2OG oxygenase was based on 14C isotopic labelling of carbon in a 2OG turnover 
assay, namely 14C isotopic labelled CO2 was produced in the presence of co-factors, 
Fe(II) and co-substrates, oxygen and ascorbate. Less CO2 was produced when 
ALKBH5 was inhibited by generic inhibitor for 2OG oxygenases, pyridine-2,4-
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dicarboxylate (2,4-PDCA), reflecting amenability to inhibition. In addition, the 
authors also identified ALKBH5 as a HIF-1α responsive gene where ALKBH5 gene 
has two HIF binding sites at its promoter. Lastly, the authors discovered that 
ALKBH5 localise mainly in the nucleus of cells, similar to FTO, and postulated that 
ALKBH5 is a DNA repair enzyme. 
In 2013, it was reported that ALKBH5 shares the same substrate as FTO and was 
inactive against dsDNA [44]. ALKBH5 is able to demethylate m6A in mRNA and is 
linked to fertility. They further confirmed that ALKBH5 is localised in the nuclear 
speckle. However, ALKBH5 does not play a DNA repair function as previously 
proposed. The discovery of ALKBH5 represents the second enzyme after FTO, which 
is able to remove the dynamic modification, m6A in mRNA[236]. Despite the 
identification of ALKBH5 as epigenetic regulatory enzyme, the exact molecular 
mechanism of how ALKBH5 performs its biology roles remains elusive.  
The first crystal structure of ALKBH5 was first reported in 2014 [186, 237-240], 
revealing a crystallographic dimer. The dimer-dimer interaction was aided by the π- π 
stacking interaction of IOX3 (compound name given by the authors), covalently 
linked to the surface of the active domain. ALKBH5 displayed the characteristic 
DSBH fold of human AlkB family of 2OG oxygenases. The manganese divalent ion 
(in place of ferrous iron) is ligand by the motif, a HxD/E...H triad (x being any amino 
acid residue) which are generally conserved across the 2OG oxygenases family. 
Nevertheless, the first crystal structure of ALKBH5 gave some insights towards its 
substrate preference. Similarly to FTO, two NRLs precede the DSBH fold. NRL1 of 
ALKBH5 (3 residues) is much shorter than that of FTO (~15 residues) while NRL2 of 
ALKBH5 longer and disordered (~14 residues) than that of FTO (~10 residues). Both 
longer NRLs of ALKBH5 and FTO contain some positively charged and aromatic 
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residues such as arginine, lysine, and tyrosine, which interact with the oligonucleotide. 
An additional interesting observation was that the βIV/V loop of ALKBH5 is 
stabilised by disulphide bond formation between Cys230 and Cys267 of βVII. This 
rigidified loop might serve to block out dsDNA as observed when ALKBH5 is 
superimposed with AlkB and ALKBH2 complexed with dsDNA. This could confer 
stricter substrate specificity towards single stranded oligonucleotide. The first 
reported crystal structure of ALKBH5 was followed by co-crystal structures of 
ALKBH5 with various generic inhibitors such as NOG, 2,4-PDCA and small 
molecules from crystallisation conditions. 
Just recently, ALKBH5 is found to have a direct role in breast cancer stem cells 
(BCSCs) proliferation [241]. Exposure of BCSCs to hypoxic environment stimulates 
expression of HIF-1α and HIF-2α which binds to the promoter upstream of ALKBH5 
gene. ALKBH5 demethylate m6A found in NANOG mRNA, a pluripotency factor, 
which then promote the BCSCs proliferation. Knockdown of ALKBH5 will prevent 
BCSCs proliferation. Thus, this finding demonstrated the potential for ALKBH5 to be 
a therapeutic target. 
For a better understanding of the biological function of ALKBH5, some questions 
need to be addressed. For instance, what is the difference between substrate 
preference of ALKBH5 and FTO given that they play distinct biological roles? In 
addition, the same preference of both ALKBH5 and FTO to single stranded m6A-





1.5 Amenability to small molecule inhibition 
As aforementioned, human 2OG oxygenases are implicated in many diseases. Thus, it 
is of significant interest to investigate whether human 2OG oxygenases are viable 
targets for therapeutic intervention. As such, over the years, there are many reports, 
patents and reviews of the design of small molecule inhibitors and drugs that target 
the enzymatic activities of human 2OG oxygenases such as (JmjC)-type 2OG 
oxygenases and PHDs [242-244]. Crystal structures of human 2OG oxygenases 
greatly facilitate the rational drug design. Thus, it has opened up the possibility to 
develop specific and potent small molecules that target human 2OG oxygenases. 
Some of the potential drugs have an IC50 at nM range. In addition, some of the drugs 
have entered clinical trials and the clinical studies effort is still ongoing [242, 243]. 
We are starting to gain a foothold regarding the understanding of the human AlkB 
family of 2OG oxygenases. There are documentations of some of the human AlkB 
family members implicated in various diseases, most probably through covalent 
modifications of nucleobases in DNA and RNA. These warrant the investigation on 
the potential of inhibiting the activity of human AlkB family of 2OG oxygenases by 
small molecules for probes and drugs development. The E.coli AlkB can be 
enzymatically inhibited by NOG, with an IC50 of ~700 μM [204]. Arguably, this is the 
first indication of the ability of AlkB family of 2OG oxygenases to be enzymatically 
inhibited. NOG is able to weakly inhibit all the human members of 2OG oxygenases 
family and is considered a 'generic' inhibitor. The promiscuity of NOG is not 
surprising as the binding mechanism primarily depends on the binding to the catalytic 
triad, very much well conserved across the members of 2OG oxygenases family 
forming similar interactions as 2OG [245]. NOG is a competitive inhibitor, occupying 
the same position as 2OG in the catalytic domain, chelating to the co-factor iron (II). 
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In 2012, AlkB was crystallised with various inhibitors that is more complex than 
NOG [205]. These inhibitors have extra aromatic functional groups extended from the 
alkyl backbone of NOG, embedding into a hydrophobic sub-pocket next to a His187 
(one of the catalytic triad residues of AlkB) and Trp178 of AlkB. This shows that high 
potency and selectivity could potentially be obtained for human AlkB family of 2OG 
oxygenases’ inhibitors, by taking advantage of the residues in adjacent sub-domains, 
which may not be as well conserved as the catalytic triad. Just recently, another class 
of inhibitor for AlkB was reported. Rhein, a natural product, occupies the substrate 
binding site of AlkB [207]. This further illustrates that surrounding residues, other 
than the 2OG binding pocket, could be exploited for inhibitors and probes design. 
FTO is directly linked to obesity. Hence, it has gathered much interest in developing 
probes and drugs in hope to shed light on the biology and potential therapeutic 
purposes. Reports of potent and selective inhibitors have steadily increased since 2012 
[245-253]. Different strategies such as in silico screening and rational design were 
employed to identify inhibitors for FTO such as rhein and meclofenamic acid [246, 
249]. Various approaches such as biophysical assays, biochemical assays, cell-based 
assays and X-ray crystallography were used for hit validation and characterisation. 
One challenge was to discover potent and selective inhibitors that can specifically 
inhibit FTO through different mode of binding. Gratifyingly, FTO demonstrated the 
ability to be inhibited by different classes of inhibitors through various binding 
mechanisms. We are possibly the first to contribute, via a novel tethering 
methodology to discover a class of inhibitor [245]. The inhibitors act through a unique 
binding mechanism, which will be further discussed in this thesis.  
As mentioned earlier in this thesis, ALKBH3 has been a subject for therapeutic 
intervention. The research group designed and attempted to optimise the 
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bioavailability of the ALKBH3 inhibitor, HUHS015 [232]. However, it will be 
interesting to understand the binding mechanism of HUHS015 through structural 
approaches. There are reports that claimed the presence of inhibitors for ALKBH5. 
However, both are weak and non-selective. In addition, it will be valuable to develop 
inhibitors for ALKBH1, ALKBH2 and ALKBH5. Nevertheless, FTO is the first 
human AlkB family of 2OG oxygenases to be potently and selectively inhibited in my 
thesis. This successful demonstration paves way for the probe and drug design of 
other members of human AlkB family of 2OG oxygenases, mentioned above, despite 














1.6 Aims and significance of the project 
Human AlkB family of 2OG oxygenases are demethylases mainly involved in nucleic 
acid repair and epigenetic modification. They have attracted much interest due to their 
implication in various human diseases making them potential therapeutic targets. FTO 
is a member of the AlkB family, which demethylates m6A [43]. M6A is a recently 
identified epigenetic mark on RNA that plays a role in transcript RNA splicing, 
stability, translation and localisation [126]. FTO is the first GWAS identified obesity 
gene [143]. Particularly, functional FTO is important for normal growth and 
development in humans [177]. However, the biology of m6A demethylation by FTO 
is unclear. Furthermore, human AlkB homolog ALKBH5 is also able to perform m6A 
demethylation, making it challenging to elucidate the roles and functions of FTO [44]. 
Presence of m6A in mRNA weakens Watson-Crick base pairings but does not prevent 
duplex formation [130, 131]. Depending on sequential context, the m6A mark might 
influence the different secondary structures adopted by mRNA, therefore affecting the 
availability of binding factors to intearact with mRNA to trigger downstream 
biological events [127]. FTO and ALKBH5 are the only known m6A demethylases in 
human and they seemingly demethylate m6A selectively. However, it remains unclear 
about the enzymes’ substrate recognition mechanism towards m6A-induced 
conformation in mRNA.  
This thesis aims to address the following issues: 
1) To repeat and establish crystallisation condition for FTO that can achieve routine 
diffraction to atomic resolution for structure-based small molecules inhibitory studies. 
This was achieved by optimisation of the purification protocol and systematic 
screening of precipitants and additives of the crystal hit condition. 
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2) To develop a potent and selective inhibitor for FTO and understand the mechanism 
of inhibition, setting a platform for probe development and therapeutic purposes. We 
managed to solve the structures of co-crystal complexes of FTO with various 
inhibitors. Next, we were able to analyse and understand the mechanism for potent 
and selective inhibition of FTO.  
3) To investigate how FTO and hALKBH5 recognise different conformations of 
mRNA mediated by m6A. We discovered that FTO and hALKBH5 were able to 
recognise and discriminate m6A-containing oligonucleotides of almost similar 
sequences but different conformations in vitro. In addition, FTO and hALKBH5 were 
able to affect a conformational change of the oligonucleotides upon demethylation.  
FTO gene has a direct link to obesity and FTO is an m6A demethylase with 
epigenetic implications. Structural understanding of the potency and selectivity of an 
FTO inhibitor will set a good platform for probing the biology of FTO. This will also 
provide a foundation for therapeutic intervention. A better understanding of the 
interplay between FTO demethylation and m6A determined conformational changes 



























2.1 Molecular cloning and small scale protein expression 
The human full length FTO construct was kindly provided by Dr. Giles Yeo 
(University of Cambridge Metabolic Research Lab) for this study. Other cDNAs used 
in this thesis were kindly provided by Protein Production Platform (PPP), NTU. 
Molecular cloning and small scale expression analysis of FTO, ΔN31-FTO, E.coli 
ΔN11-AlkB and ALKBH5 (residues 66-292): Truncations of proteins were selected 
based on previously reported enzymatically active constructs. The cloning vector 
pNIC28-Bsa4 (GenBank accession EF198106), developed by Opher Gileadi at SGC 
Oxford was constructed by the help of PPP, NTU [254, 255]. Briefly, ligase 
independent cloning (LIC) technology was employed with RecA- strain of E.coli for 
cloning and amplification of vector containing gene insert. The gene is fused with N-
terminal hexa-histidine tag for downstream nickel affinity purification and TEV-
protease cleavage site for optional tag removal. The construct is then re-transformed 
into E.coli expression strain (T1-phage resistant BL21-DE3 Rosetta) developed by 
PPP. The clone was put through a small scale expression screening by PPP to test for 
soluble expression. Briefly, cultures are grow in 1 mL of terrific broth at 37°C and 
induced by IPTG when the optical density at 600 nm (OD600) reached 2-3. The 
temperature is lowered to 18°C upon induction. After overnight culture, the cells are 
harvested and lysed, then the supernatant clarified by centrifugation was applied for 
nickel affinity chromatography to assess the solubility and relative abundance of 




Molecular cloning of ΔN31-FTO: The cloning of the truncated FTO was performed 
using the human full length FTO construct provided by Dr. Giles Yeo as cDNA 
template. The cDNA coding for ΔN31-FTO was amplified using polymerase chain 
reaction (PCR) with two primers (forward, 5'-
GGAATTCCATATGACCCCCAAAGATGATGA-3' and reverse, 5'-
CCCAAGCTTCAGGGTTTTGCTTCCAGAA-3') with NdeI and HindIII restriction 
sites. The PCR product and the vector pET28b are digested by the respective 
restriction enzymes and ligated by ligase. The ligated products were then transformed 
into DH5α and plated onto an agar plate overnight at 37°C. Colony PCR was then 
performed to check for insertion, subsequently sequencing to verify that there are no 
frameshift and mutation for the truncated gene insert. The FTO construct is fused with 
N-terminal hexa-histidine tag for downstream nickel affinity purification and 
thrombin protease cleavage site for optional tag removal. The constructed plasmid is 
then re-transformed into E.coli BL21 (DE3) for protein preparation. 
Molecular cloning and small scale expression analysis of ALKBH2 (residues 56-
258): The cloning of the truncated ALKBH2 was performed using cDNA template 
kindly provided by PPP, NTU. The PCR amplification for ALKBH2 (residues 56-258) 
was carried out using two primers (forward, 5'- 
GGAATTCCATATGAGCTGGCGGCACATTC-3' and reverse, 5'- 
CCCAAGCTTCAAAGCAAAATTTTACGAAAAGT-3') with NdeI and HindIII 
restriction sites. The amplicons and the vector pET28b are digested by the respective 
restriction enzymes and ligated by ligase. The ligated products were then transformed 
into DH5α and plated onto an agar plate overnight at 37°C. Colony PCR was then 
performed to check for insertion into the vector. The vector was then sequenced to 
verify that there are no frameshift and mutation for the truncated gene insert. The 
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ALKBH2 (residues 56-258) construct is fused with N-terminal hexa-histidine tag for 
downstream nickel affinity purification and thrombin protease cleavage site for 
optional tag removal. The plasmid is consequently re-transformed into E.coli BL21 
(DE3) for protein expression. Small scale expression test was carried out. Briefly, 50 
mL of 2XTY growth medium was inoculated with 500 μL of start culture at 37°C and 
200 rpm. When OD600 reached around 0.6-0.8, protein expression was induced by 0.5 
mM IPTG (Gold Biotechnology). The temperature is lowered to 16°C upon induction. 
After overnight culture, the cells are lysed, clarified and nickel affinity 
chromatography was performed to assess the solubility and relative abundance of 
protein via SDS-PAGE. 
Molecular cloning and small scale expression analysis of YTHDF2 (residues 385-
576): The cloning of the truncated YTHDF2 was performed using cDNA template 
kindly provided by PPP, NTU. The PCR amplification for YTHDF2 (residues 385-
576) was carried out using two primers (forward, 5'-
CGGGATCCATGCCCCACCCAGTGTTGG-3' and reverse, 5'-CCCTCGAG 
TCAACCTTGACGTTCCTTTTTAA-3') with BamHI and XhoI restriction sites. The 
amplicons and the vector pGEX-6P-1 is digested by the respective restriction 
enzymes and ligated by ligase. The ligated products were then transformed into DH5α 
and plated onto a agar plate overnight at 37°C. Colony PCR was then performed to 
check for insertion into the vector. The vector was then sequenced to verified that 
there are no frameshift and mutation for the truncated gene insert. The YTHDF2 
(residues 285-576) is fused with N-terminal glutathione S-transferase (GST) tag for 
downstream gluthione sepharose affinity purification and PreScissionTM protease 
cleavage site for optional GST tag removal. The plasmid is consequently re-
transformed into E.coli BL21 (DE3) for protein expression. Small scale expression 
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test was carried out. Briefly, 50 mL of 2XTY growth medium was inoculated with 
500 μL of start culture at 37°C and 200 rpm. When OD600 reached around 0.6-0.8, 
protein expression was induced by 0.5 mM IPTG (Gold Biotechnology). The 
temperature is lowered to 16°C upon induction. After overnight culture, the cells are 
lysed, clarified and glutathione sepharose affinity chromatography was performed to 
assess the solubility and relative abundance of protein via SDS-PAGE. 
2.2 Large scale protein preparation 
ALKBH3 (residues 1-286, fused to 39-amino acid histidine tag at the N-terminal) 
used for biochemical assays in this thesis was commercially purchased from ProSpec-
Tany Technogene Ltd, Israel. We eventually managed to optimise the purification 
protocol and routinely obtain ALKBH3 with high yield and high purity. Full length 
PHD2 (fused to MYC/DKK tag at C-terminal) was purchased from Origene 
Technology, USA. 
Large scale preparation of FTO: BL21 (DE3) Rosetta T1R transformed with 
pNIC28-Bsa4 FTO was grown in 6 L 2XTY media supplemented with 
chloramphenicol (33 μg/mL) and kanamycin (30 μg/mL) at 37°C and 200 rpm to an 
OD600 of ~0.6-0.8. Protein expression was induced by addition of 0.5 mM IPTG (Gold 
Biotechnology). Cell was continuously grown for 16 hours at 16°C before harvested 
by centrifugation. The cell pellet can be stored at -80°C for future purification or can 
be immediately suspended to homogeneity in 25 mM Tris, pH 7.5, 500 mM NaCl, 40 
mM imidazole, pH 7.5 and 5 mM β-ME. Purification was performed at 4°C. Cells 
were disrupted by French press and the lysate clarified by centrifugation and filtration. 
FTO was purified from crude cell lysate by passing through the Ni-NTA affinity 
column (GE healthcare), then eluted with a gradient increase of imidazole up to 500 
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mM. Further purification was performed by size exclusion chromatography using 
HiLoad superdex 200 26/60 (GE Healthcare), simultaneously with buffer exchanged 
to 25 mM Tris, pH 7.5, 100 mM NaCl, 5% (v/v) glycerol and 5mM β-ME. Final 
protein purity and concentration was determined via SDS-PAGE and NanoDrop 
2000c UV-Vis spectrophotometer (Thermo Scientific), respectively. 
Large scale preparation of ΔN31-FTO: BL21 (DE3) transformed with pET-28b 
FTO was grown 6 L 2XTY media supplemented with chloramphenicol (33 μg/mL) 
and kanamycin (30 μg/mL) at 37°C and 200 rpm to an OD600 of ~0.6-0.8. Protein 
expression was induced by addition of 0.5 mM IPTG (Gold Biotechnology). Cell was 
continuously grown for 16 hours at 16°C before harvested by centrifugation. The cell 
pellet can be stored at -80°C for future purification or can be immediately suspended 
to homogeneity in 25 mM Tris, pH7.5, 500 mM NaCl, 40 mM imidazole, pH 7.5 and 
5 mM β-ME. Purification was performed at 4°C. Cells were disrupted by French press 
and the lysate clarified by centrifugation and filtration. FTO was purified from crude 
cell lysate by passing through the Ni-NTA affinity column (GE healthcare), then 
eluted with a gradient increase of imidazole up to 500 mM. It was followed by anion 
chromatography using a 5 mL HiTrap Q HP column (GE Healthcare), with gradient 
elution to 1M NaCl. Further purification was performed by size exclusion 
chromatography using HiLoad superdex 200 26/60 (GE Healthcare) buffer exchanged 
into 25 mM Tris, pH 7.5, 50 mM NaCl and 5 mM β-ME. Final protein purity and 
concentration was determined via SDS-PAGE and NanoDrop 2000c UV-Vis 
spectrophotometer (Thermo Scientific), respectively. 
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Large scale preparation of ΔN11-AlkB: AlkB purification was performed by PPP 
[254, 255]. BL21 (DE3) Rosetta T1R transformed with pNIC28-Bsa4 ∆N11 AlkB 
were grown in a LEX system using 750 mL of Terrific Broth (TB) supplemented with 
8 g/L of glycerol and appropriate antibiotics. The culture was incubated at 37°C in the 
LEX system with aeration and agitation through the bubbling of filtered air through 
the culture. When the OD600 reached ~2, the temperature was reduced to 18°C and 
the cultures were induced after 30 to 60 min by addition of 0.5 mM IPTG. Growth 
was continued for 16-20 h and harvested by centrifugation. The cell pellets were 
suspended in 1.5 times the cell pellet weight of lysis buffer containing 100 mM 
HEPES, 500 mM NaCl, 10 mM Imidazole, 10% glycerol, 0.5 mM TCEP, pH 8.0, 
Benzonase (4 uL per 750 mL cultivation) 250 U/uL from Merck, Protease Inhibitor 
Cocktail Set III, EDTA free (1000x dilution in lysis buffer) from Calbiochem and 
stored at -80°C. Cells were lysed on ice by sonication, and the lysate cleared by 
centrifugation and filtration. Filtered lysates were loaded onto 1 mL Ni-NTA 
Superflow (Qiagen) in IMAC Wash buffer 1 (20 mM HEPES, 500 mM NaCl, 10 mM 
imidazole, 10 % (v/v) glycerol, 0.5 mM TCEP, pH 7.5) and subsequently washed with 
IMAC Wash buffer 2 (20 mM HEPES, pH7.5, 500 mM NaCl, 25 mM imidazole, 10% 
(v/v) glycerol, 0.5 mM TCEP). Bound proteins were eluted with 500 mM imidazole 
and loaded onto a HiLoad 16/60 Superdex-200 column (GE Healthcare) pre-





Large scale preparation of ALKBH2 (residues 56 -258): BL21 (DE3) transformed 
with pET-28b ALKBH2 (residues 56-258) was grown in 6 L 2XTY media 
supplemented with chloramphenicol (33 μg/mL) and kanamycin (30 μg/mL) at 37°C 
and 200 rpm to an OD600 of ~0.6-0.8. Protein expression was induced by addition of 
0.5 mM IPTG (Gold Biotechnology). Cell was continuously grown for 16 hours at 
16°C before harvested by centrifugation. The cell pellet can be stored at -80°C for 
future purification or can be immediately suspended to homogeneity in 50 mM 
sodium phosphate, pH8, 300 mM NaCl, 10% (v/v) glycerol and 5 mM β-ME. 
Purifcation was performed at 4°C. Cells were disrupted by French press and the lysate 
clarified by centrifugation and filtration. ALKBH2 was purified from crude cell lysate 
by passing through the Ni-NTA affinity column (GE healthcare), with gradient elution 
to 500 mM imidazole. It was followed by affinity chromatography using a 5 mL 
HiTrap Heparin HP column (GE Healthcare), with gradient elution to 1M NaCl. 
Further purification was performed by size exclusion chromatography using HiLoad 
superdex 75 16/60 (GE Healthcare) buffer exchanged into 10 mM Tris, pH 8, 100 
mM NaCl and 5 mM β-ME. Final protein purity and concentration was determined 
via SDS-PAGE and NanoDrop 2000c UV-Vis spectrophotometer (Thermo Scientific), 
respectively. 
Large scale preparation of ALKBH5 (residues 66 -292): BL21 (DE3) Rosetta T1R 
transformed with pNIC28-Bsa4 ALKBH5 (residues 66-292) was grown in 6 L 2XTY 
media supplemented with chloramphenicol (33 μg/mL) and kanamycin (30 μg/mL) at 
37°C and 200 rpm to an OD600 of ~0.6-0.8. Protein expression was induced by 
addition of 0.5 mM IPTG (Gold Biotechnology). Cell was continuously grown for 16 
hours at 16°C before harvested by centrifugation. The cell pellet can be stored at -
80°C for future purification or can be immediately suspended to homogeneity in 50 
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mM tris, pH8, 500 mM NaCl, 40 mM imidazole, pH8 and 5 mM β-ME. Purification 
was performed at 4°C. Cells were disrupted by French press and the lysate clarified 
by centrifugation and filtration. The protein was purified from crude cell lysate by 
passing through the Ni-NTA affinity column (GE healthcare), with gradient elution to 
500 mM imidazole. It was followed by anion chromatography using a 5 mL HiTrap Q 
HP column (GE Healthcare), with gradient elution to 1M NaCl. Further purification 
was performed by size exclusion chromatography using HiLoad superdex 75 26/60 
(GE Healthcare) buffer exchanged into 20 mM Tris, pH 8, 100 mM NaCl and 5mM β-
ME. Final protein purity and concentration was determined via SDS-PAGE and 
NanoDrop 2000c UV-Vis spectrophotometer (Thermo Scientific), respectively. 
Large scale preparation of GST-YTHDF2 (residues 385-576): BL21 (DE3) 
transformed with pGEX-6P-1 YTHDf2 (residues 385-576) was grown in 6 L 2XTY 
media supplemented with chloramphenicol (33 μg/mL) and ampicillin (100 μg/mL) at 
37°C and 200 rpm to an OD600 of around 0.6-0.8. Protein expression was induced by 
addition of 0.5 mM IPTG (Gold Biotechnology). Cell was continuously grown for 16 
hours at 16°C before harvested by centrifugation. The cell pellet can be stored at -
80°C for future purification or can be immediately suspended to homogeneity in 50 
mM tris, pH 8, 500 mM NaCl and 5 mM β-ME. Purification was performed at 4°C. 
Cells were disrupted by French press and the lysate clarified by centrifugation and 
filtration. The protein was purified from crude cell lysate was load into 5 mL GSTTM 
HP column (GE Healthcare). The protein was eluted with 50 mM tris, pH8, 300 mM 
NaCl, 10 mM glutathione and 5mM β-ME. Further purification was performed by size 
exclusion chromatography using HiLoad superdex 200 26/60 (GE Healthcare) and 
buffer exchanged into 20 mM Tris, pH 8, 150 mM NaCl and 5 mM β-ME. Final 
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protein purity and concentration was determined via SDS-PAGE and NanoDrop 
2000c UV-Vis spectrophotometer (Thermo Scientific), respectively. 
2.3 Differential scanning fluorimetry (DSF)-based binding assay 
DSF-based assay for FTO was performed by the lab of Dr Esther Woon [256]. DSF-
based binding assays were performed using a MiniOpticon™ Real-Time PCR 
Detection System (Bio-Rad), monitoring protein unfolding using SYPRO orange 
(Invitrogen) according to the reported method. FAM (492 nm) and ROX (610 nm) 
filters were used for excitation and emission respectively. Reaction mixes contained 2 
μM protein, 50 μM MnCl2, 100 μM compounds, 5X SYPRO orange in a final volume 
of 50 μl. Reagents were prepared in 50 mM HEPES buffer, pH 7.5 excluding metals, 
which were dissolved as 100 mM stocks in 20 mM HCl, then further diluted in MilliQ 
water. Compounds tested were prepared in 100% DMSO and added such that the final 
concentration of DMSO was no more than 1% v/v of assay mix. Fluorescence 
readings were taken every 1°C in a range of 25-95°C, with the temperature increased 
linearly at a rate of 1 °C min-1. The software provided was used to perform global 
minimum subtraction. The inflection point, representing Tm, was calculated by fitting 
the Boltzmann equation to the sigmoidal curves obtained; data were processed using 
GraphPad Prism 6.0™. The Tm shift caused by the addition of small molecules/ 
fragments was determined by subtraction of the “reference” Tm (protein incubated 
with metal and 1% v/v DMSO) from the Tm obtained in the presence of the compound. 
The assay was performed in triplicate for each inhibitor, with standard deviations 




2.4 High performance liquid chromatography (HPLC)-based inhibition assay 
HPLC-based assay were performed by the lab of Dr Esther Woon with modifications 
from previously published protocols [91, 246, 257]. Briefly, the assays were 
performed in triplicate for each inhibitor, with a final reaction volume of 25 μL. In 
general, each reaction consisted of the 2OG oxygenase (1 - 4 μM), 2OG (50 - 150 
μM), (NH4)2Fe(SO4)2.6H20 (150 μM), L-ascorbate (2 mM) and methylated substrate 
(10-100 μM) in 50 mM HEPES buffer, pH 7.5 and inhibitors at various concentrations 
(final DMSO concentration no more than 1% v/v of assay mix). The reactions were 
typically incubated at 4°C or room temperature for 30 min to 1 h. Demethylation of 
substrates were quantified by HPLC system separated by Zorbax C18 column (4.6 
mm x 250 mm) or Dionex DNAPac PA200 anion-exchange column (8 μm, 4 mm x 
25 mm). The UV detection wavelength was set at 266 nm. The percentage inhibition 
was estimated based on integrated peak areas of substrates and product. MALDI-TOF 
MS was also used to quantify the demethylation of some methylated oligonucleotides 
via estimation based on relative intensities observed in the mass spectra. Typically, 
eight different concentrations (0, 1, 3, 10, 30, 100, 300, 1000 μM) of inhibitors were 
used for IC50 determination, which is calculated using nonlinear regression, with 







2.5 MTT cell viability assay 
MTT cell viability assay was performed by the lab of Dr Esther Woon with some 
modifications [246]. Human HeLa cells were seeded in 96-well plates at a density of 
1x104 cells/well, and allowed to grow for 24 h before being exposed to varying 
concentrations of compound 25 (0, 5, 10, 50 and 100 µM). Cells that were treated 
with 1% v/v DMSO served as negative control. After incubation at 37°C for 24 h, the 
supernatant was removed, and each well was washed twice with PBS. 20 μL of MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (5 mg/ml in 
PBS) and 100 μL of medium were then introduced, and the solution was incubated at 
37°C for another 4 h. The resultant formazan crystals were dissolved in 100 μL 
DMSO and its concentration is determined by measuring its absorbance intensity at 
570 nm using a microplate reader. A background wavelength of 630 nm was used. 
Cell viability was presented as a percentage relative to the untreated control cells. All 
experiments were performed in triplicate.  
2.6 Cell-based inhibition assay 
Cell-based inhibition assay was performed by the lab of Dr Esther Woon. The assay 
was performed as previously reported [246]. Human HeLa cells were treated with 
either 10 µM or 50 µM of compound 25 or with 1% v/v DMSO (negative control) and 
allowed to incubation at 37°C for 6 h. Then the cells were harvested and the total 
RNA were isolated with TRAZOL Reagent (Invitrogen). Subsequently, the mRNA 
was extracted using PolyATtract® mRNA Isolation Systems (Promega), and the 
rRNA contaminants were removed using RiboMinus Transcriptome Isolation Kit 
(Invitrogen). The concentration of the resultant mRNA was measured using 
NanoDrop. 
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To digest the mRNA to individual nucleotides, 1 μg of mRNA was treated at 37ºC for 
1 hour with 2 Units of nuclease P1 in 40 μL buffer containing 25 mM of NaCl, and 
2.5 mM of ZnCl2, followed by the addition of 1 M NH4HCO3 (3 μL), and alkaline 
phosphatase (0.5 Unit). After incubation at 37ºC for 3 h, the solution was diluted 3 
times, and analyzed by a HPLC system. The nucleosides were separated using a 
Zorbax C18 column (4.6 mm x 250 mm), eluted by solution mixture of solvent A 
(water + 0.1% TFA) and solvent B (MeOH), with a gradient decrease of solvent A (95% 
to 40%) over 8 min, at a flow rate of 1mL/min at room temperature. The UV detection 
wavelength was set at 266 nm. The concentrations of N6-methyladenine (m6A) and 
adenine (A) were determined based on their peak areas, using calibration plots 
obtained from pure nucleoside standards. The percentage of m6A/A was then 
obtained using the calculated concentrations.  
2.7 Screening and optimisation for FTO crystallisation condition 
Screening for FTO crystallisation condition: ΔN31-FTO at concentrations of 6 
mg/mL, 8 mg/mL and 12 mg/mL were subjected to co-crystallisation screening. Co-
crystallisation mixture consisted of ΔN31-FTO, nickel (II) chloride and NOG or 2,4-
PDCA. Crystallisation screening was performed using an automated liquid handling 
robot, Phoenix (Art Robbins Instruments) dispensing sample drops into microplate 
(INTELLI-PLATE® 96) at three different protein sample to reservoir ratios (1:2, 1:1, 
and 2:1). Commercial screening kits from Hampton Research and Emerald 
BioSystems were used for initial high throughput screening. After dispensing, the 
microplates are sealed by a UV transmissible film, spin down and stored in Rock 
Imager (Formulatrix) at 4°C and 20°C for scheduled imaging. Initial protein crystal 
formation was judged by visible light photos and trans UV illumination. 
 58 
Optimisation of FTO crystallisation condition: Grid screening was carried out 
using a 24 well VDX plate (Hampton Research). The optimisation was performed 
using hanging drop vapour diffusion at 20°C. The pH of crystallisation buffer, 100 
mM sodium citrate was varied from 5.0 to 6.5 across the row while the percentages of 
the additive, iso-propanol were varied from 2% (v/v) to 20% (v/v) across the column. 
Additives (methanol, ethanol, n-butanol and t-butanol) that have structural 
resemblance to isopropanol were used at various percentages (v/v) during the 
optimisation screening in place of isopropanol. Different percentages (w/v) of 
polyethylene glycol (PEG) precipitant 3350 and 4000 were varied from 5 to 20% w/v 
in the optimisation drop. Each well consisted of 400 μL of the reservoir solution. The 
ratios of protein to reservoir solution were 2 μL : 1 μL, 1 μL : 1 μL and 1 μL : 2 μL, 
respectively.  
2.8 FTO complex co-crystallisation 
Crystals of ∆N31-FTO in complex with compounds 12, 16, and 21 were grown in 
hanging drops at 20°C using hanging drop vapour diffusion methods. The ratio of 
protein to reservoir solution was 2:1 (total drop volume: 2.25 μL). The sample 
contained 8 mg/mL protein and 1.5 mM ligand, in the buffer 25 mM Tris, pH 7.5, 50 
mM NaCl, 5 mM β-ME, 1 mM NiSO4. The reservoir solutions for ∆N31-FTO in 
complex with 12, 16, and 21 contained 100 mM sodium citrate, pH 5.6, 10-12% w/v 
polyethylene glycol (PEG) 3350, 10-15% t-butanol. After 1 week, the crystals were 





2.9 Data collection and structural refinement 
Crystal screening and data collection was carried out at the Swiss Light Source (SLS), 
Switzerland. Crystal diffraction data of protein ∆N31-FTO complexed with 12 and 16 
were screened and collected on PXI beamline of SLS. Crystal diffraction data of 
∆N31-FTO protein complexed with 21 were screened and collected on PXIII 
beamline of SLS. All diffraction data were collected at 100K, then indexed, integrated, 
scaled and merged by X-ray Detector Software (XDS) [258]. The phases were 
determined and solved by molecular replacement using Phaser-MR subroutine in 
Phenix with 4IE5 (PDB ID) as a search model [259]. The correctness of the molecular 
replacement was determined by the translation function Z (TFZ) and log-likelihood 
gain (LLG) score [260]. Iterative rounds of refinement and model building were 
carried out using Phenix and COOT, respectively, until Rwork and Rfree no longer 
converge [261]. The PDB coordinate models of the inhibitors were generated by 
PRODRG [262]. The geometry and metal ion coordination restraint files for 
refinement were prepared by ReadySet subroutine in Phenix. 
2.10 Computational tool for protein-oligonucleotide energy minimisation 
PDB models were prepared using PyMOL prior to submission to the YASARA 
energy minimisation server [263]. The fitting of 5'-GGm6ACU-3' onto the domains of 
both FTO (PDB ID 3LFM) and ALKBH5 (PDB ID 4NRO) was by superimposing 
AlkB (PDB ID 4NID) using pymol. The m6A containing dsDNA was then edited by 
PyMOL leaving 5'-GGm6ACU-3' placed in the domain of FTO and ALKBH5. Both 
PDB models were then submitted to YASARA energy minimisation server. 
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2.11 Circular dichroism (CD) spectroscopy 
CD spectra were obtained with a JASCO J810 spectro-polarimeter. Oligonucleotides 
were prepared in 10 mM sodium phosphate, pH 7.4 and 150 mM NaCl buffer. 5 μM 
of oligonucleotides (unless stated otherwise) were heated to 90°C for 5 min and re-
annealed by slow cooling to 4°C at a decrease rate of 1 °C/min.  CD spectra were 
recorded in quartz cuvettes (path length 10 mm, 400 µL) from 200 nm to 350 nm 
using a 10 nm/min scan speed, with a spectral band width of 1 nm and a time constant 
of 4 s. All the spectra were subtracted with the buffer blank and smoothed using the 
Savitsky-Golay algorithm (polynomial order 10). 
2.12 Non-denaturing polyacrylamide gel electrophoresis (PAGE) analysis 
Annealed oligonucleotides were loaded to 20% native polyacrylamide gel and 
electrophoresis was performed at 4°C in Tris/Borate/EDTA (TBE) running buffer 
made up of 90 mM Tris, pH 8.3, 90 mM boric acid and 5 mM EDTA. The gel were 
stained with SYBR® Gold Nucleic Acid Gel Stain and visualised by Gel Dock XR + 
(Bio-Rad) and Image Lab 4.0 software (Bio-Rad). The fraction of monomolecular 
hairpin structures was evaluated based on the assumption that the efficiency of the 
staining of the base pairs in a hairpin was similar to that in a biomolecular duplex. 
2.13 Electrophoretic mobility shift assay (EMSA) 
RNA probes that were labelled at their 3’-ends with biotin were purchased from Keck 
Foundation Biotechnology Resource Laboratory. Prior to electrophoresis, 2 μL of 
annealed RNA probes (4 nM final concentration) were incubated with 2 μL of FTO or 
ALKBH5 or YTHDF2 (0.02, 0.5, 1, 2, 5 μM, and other concentrations as indicated) at 
4°C for 30 min in a binding buffer containing 10 mM HEPES, pH 7.3, 5% glycerol, 
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20 mM KCl, 1 mM MgCl2, 1 mM DTT and 8 U RNasin® Ribonuclease Inhibitor 
(Promega). 20 uL of the RNA-protein mixture was loaded to 7.5% native 
polyacrylamide gel and electrophoresis was performed at 4°C for 90 min at 90 V 
using TBE running buffer. Electrophoresis for ALKBH5 and FTO were performed in 
buffer without EDTA. Visualisation was carried out using CL-XposureTM Film 
(Thermo Scientific), Gel Dock XR+ (Bio-Rad) and Image Lab 4.0 software (Bio-Rad). 
2.14 Microscale thermophoresis (MST) measurement 
MST experiments were performed on a Monolith NT Label Free system 
(NanoTemper Technologies) at 25°C using 40% MST power, and 60% LED power 
for FTO and 40% LED power for ALKBH5 [264], respectively. Laser on and off 
times were set at 30 s and 5 s, respectively. Zero background standard treated 
capillaries (NanoTemper Technologies) were used. All experiments were performed 
in triplicates. Oligos for MST measurement were purchased from DharmaconTM. For 
determination of binding affinity with FTO, twelve different concentrations of RNA 
ranging from 1 mM to 490 nM were used. The annealed RNAs were incubated with a 
mixture of FTO/NiSO4 complex (100 nM/1 mM) and NOG (500 μM) in 50 mM Tris 
buffer, pH 7.5,  150 mM NaCl and 0.05% Tween 20 at 25°C for 20 minutes. Data 
derived from thermophoresis measurement and temperature-dependent change in 
fluorescence (T-Jump) were used to determine the binding affinities (KD) of the RNAs. 
Curve fitting was performed using the NT Analysis software provided. For 























3.1 Bacterial expression of proteins  
Bacteria expression using engineered E. coli represents one of the fastest and easiest 
ways to prepare large amounts of recombinant proteins for structural and biochemical 
studies. Gratifyingly, most of the AlkB family of proteins we worked with in this 
thesis were able to get soluble expression using bacterial expression systems [265].  
3.1.1 Small scale protein expression check 
Small scale protein expression tests for some of the AlkB constructs fused with N-
terminal hexa-histidine tag were performed by PPP, NTU, using Ni-NTA beads (Fig. 
15A-D). Small scale protein expression check of ALKBH2 was done in-house (Fig. 
15E). The soluble expression and purity of the proteins were judged by SDS-PAGE to 
ascertain whether they are suitable for large scale preparation.  
Small scale protein expression check of the N-terminal GST-tagged YTHDF2 was 
performed using Glutathione Sepharose 4 Fast Flow (GE Healthcare) beads (Fig. 15F). 
The soluble expression and purity of the protein pull-down by glutathione was judged 
by SDS-PAGE to ascertain suitability for scaling up.  
Gratifyingly, the constructs displayed significant overexpression upon pull-down and 
















Figure 15. Small scale expression test. Lane A to D was performed by PPP. Lane 
A: ∆N11- AlkB (MW=25470 Da); Lane B: Full length FTO (MW=60966 Da); 
Lane C: ∆N31-FTO (MW=57139 Da); Lane D: ALKBH5 (AA66-292) 
(MW=28704 Da); Lane E: ALKBH2 (AA56-258) (MW=25257 Da); Lane F: GST-
YTHDF2 (385-576) (MW=49345 Da).  
 65 
3.1.2 Large scale protein preparation 
After the constructs were shown to have good soluble expression, large scale 
purification was carried out (Fig.16). Due to stringent buffer requirement, only 
purification ∆N11-AlkB was performed by PPP (Fig. 16C). Proteins after final size-
exclusion chromatography purification step were at least 95% pure by SDS-PAGE 









Figure 16. SDS-PAGE and final gel filtration profile of large scale protein 
purification. A: Full length FTO; B: ∆N31-FTO; C: ∆N11-AlkB; D: ALKBH2 
(AA56-258); E: ALKBH5 (AA66-292); F: GST-YTHDF2 (AA385-576). Fractions 
highlighted green were collected for assays and/or crystallisation. 
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3.2 Substrate selectivity of FTO and other AlkB oxygenases 
NOG binding: An analysis of substrate selectivity of FTO and other AlkB 
oxygenases was carried out prior to the commencement of the project. To do this, 
various cDNAs of AlkB oxygenases were cloned into constructs that were reported to 
result in active recombinant proteins. DSBH domain is a typical characteristic of 
AlkB oxygenases. Freshly purified recombinant proteins were probed for DSBH 
structural integrity via DSF using NOG (Table 1). In the presence of a metal (eg. 
Fe(II), Ni(II), Mn(II) or Zn(II)) and generic inhibitor NOG, thermal shifts (Tm shift) of 
more than 2°C relative to the apo proteins were observed, which was caused by 
additional stability afforded to the DSBH domains of the proteins. Note that a thermal 
shift (Tm shift) of more than 2°C is considered to be significant. In vitro enzymatic 
activity assays were also performed to test the activity of recombinant proteins. DSF 
and enzymatic assays were performed by the lab of Dr Esther Woon. 
 
Table 1. Tm shift and IC50 data of AlkB oxygenases against NOG. NOG is a 
weak to moderate inhibitor to AlkB enzymes. AlkB oxygenases generally have a 
Tm shift of more than more than 2°C for NOG. (Data obtained from Dr Esther 
Woon.) 
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M3T binding: All the AlkB recombinant proteins reported in this thesis were active 
and able to demethylate their respective N-methylated nucleotide substrates [245]. 
Consistent with the previous reports, recombinant FTO was able to demethylate m3T 
nucleotide reasonably well [91]. In line with this, DSF of FTO with m3T showed a 
large Tm shift of 12.1°C (Table 2). Demethylation of m3T was observed at very low 
efficiency for other AlkB oxygenases, with weak Tm shift observed by DSF. Notably, 
FTO was unable to demethylate m6A nucleotide although m6A containing RNA 
oligonucleotides were reported to be its 'natural' substrate. Similar to FTO, ALKBH5 
was unable to demethylate m6A mononucleoside although ALKBH5 bind strongly to 
m6A mononucleoside with an observed Tm shift of 9.8°C. The natural substrate for 
ALKBH5 was reported to be m6A. FTO and ALKBH5 were unable to bind strongly 
with oligonucleotides as observed from the Tm shift assay. Despite the weak binding, 
FTO and ALKBH5 were able to demethylate their respective m3T and m6A 
containing oligonucleotide substrates very well. 
 
 
Table 2. Tm shift data of AlkB oxygenases to m3T and m6A containing 
nucleotides. Only FTO bind to m3T strongly while only ALKBH5 bind to m6A 
strongly. All AlkB oxygenases bind weakly to 5-mer oligonucleotides. Asterisks 
(*) indicate good in vitro demethylation activity of the enzymes toward the 
substrates. (Data obtained from Dr Esther Woon.) 
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3.3 Inhibitory activity of 12 and other analogs in vitro 
Strategy employed for inhibitor design will be discussed further in chapter 4.2. 
Briefly, we have established that FTO and other human AlkB 2OG oxygenases have 
varied substrate preferences (chapter 3.2). Thus, we envisaged the design of inhibitors 
that simultaneously occupy the 2OG-binding and substrate binding sites to obtain 
potency and selectivity. Many two-component small molecules were designed, of 
which, inhibitor 12 demonstrated best profile (Table 3). 
Inhibitor 12 demonstrated the highest potency and selectivity (IC50 = 0.81 PM; Tm = 
11.2°C) among all the inhibitors studied (Table 3). Inhibitory activities profiling of 12 
and other analogs were performed by the lab of Dr Esther Woon. DSF and HPLC 
based demethylation assays were the two main assays used to identify and quantified 
the potency and selectivity of 12 and other analogs towards FTO. The table of data 
shown below are inhibitory profiles of selected small molecules bought or synthesised 
by the lab of Dr Esther Woon that are relevant to the discussion in this thesis.  
In general, fumarate hydrazide compounds give a better binding and inhibitory profile 
towards FTO. Thus, fumarate hydrazide is preferred over succinate and maleate 
hydrazide for the 2OG-binding component when designing the inhibitors. For the 
substrate-binding component, 3-pyridyl compounds preferred to bind and inhibit FTO 
compared to their 2-pyridyl counterparts. DSF and HPLC demethylation assays were 
used to quantify the binding and inhibitory activities respectively. Generally, a higher 
















Table 3. Selectivity and inhibitory profile of selected small molecules. 12 shows 
the best potency and selectivity toward FTO. Position of nitrogen in the pyridyl ring is 
crucial for selectivity and potency. (Data obtained from Dr Esther Woon.) 
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3.4 Cellular toxicity and activity of 12 
Cellular toxicity and efficacy profiling were performed by the lab of Dr Esther Woon 
(Fig. 17). The selection and discussion of data are accorded to the relevance of this 
thesis. The compound 25, an esterified form of 12, was used for cellular activity test 
to increase the penetrability and thus availability to the cells. 
HeLa cells could tolerate the treatment of 25 well. Over a 24 hours period, more than 
80% of the cell remained viable when treated with 100 μM of 25. Quantification of 
cell viability was calculated with respect to a negative control containing 1% v/v 
DMSO. 
Cells treated with 10 and 50 μM of 25 were found to have a notable increase of m6A 
in the mRNA compared to the control. The amount of m6A was quantified by UV 
absorbance using HPLC relative to known standards. It was found that there is an 
increase of 19% and 36% for cells treated with 10 and 50 μM of 25 respectively. 
Although more data points are desired, the inhibition by 25 appeared to be dose 
dependent. 
 
Figure 17. Cellular profile of 12. 25, an esterified from of 12 was used. A. Cellular 
toxicity. B. Cellular efficacy. (Data obtained from Dr Esther Woon.) 
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3.5 Crystallisation screening and optimisation 
The crystal structure of ∆N31-FTO was already reported prior to the start of this 
project [91, 247]. Initial attempts to repeat the crystallisation proved to be futile 
despite following the published protocol strictly. Co-crystallisation was performed 
during the crystallisation attempts with the Fe(II) co-factor, generic inhibitor NOG 
and co-substrate m3T. Generic inhibitor 2,4-PDCA was also tried in place of NOG for 
co-crystallisation screens. In the very first few attempts for FTO crystallisation, 
∆N31-FTO with N-terminal hexa-histidine tag and TEV linker were used. This was 
done as we believed that the relatively short linker would not interfere with the 
nucleation and crystal packing during crystallisation of FTO.  
Unable to repeat the crystallisation experiment, ∆N31-FTO was cloned into pET28b 
to resemble the construct of the first reported crystal structure, ∆N31-FTO with N-
terminal hexa-histidine tag with thrombin protease cleavage linker. However, 
numerous attempts of grid screening to explore the crystallisation space around the 
reported crystallisation (100 mM sodium citrate, pH 5.6 and 10% PEG 3350) yielded 
no sign of crystallisation. Additional variations around the reported condition were 
explored. For instance, temperature, final buffer, concentration of ∆N31-FTO and the 
ratio of protein to reservoir were varied. Despite numerous permutations around the 
reported condition, no crystallisation was observed. 
Crystal screening: Next, we decided to screen for ∆N31-FTO crystallisation 
conditions from commercial screening kits. A few concentrations (6, 8, 12 mg/mL) 
were subjected to screening.  Screening with apo protein and co-crystallisation was 
carried out. Co-factors were NiCl2, FeCl2, ZnCl2 and MnCl2. NOG and 2,4-PDCA 
were used during co-crystallisation in place for 2OG (will result in turnover) in hope 
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to stabilise the DSBH domain of FTO, thus promoting crystallisation. Gratifyingly, 
crystals were finally obtained in PEGRx (Hampton Research) screening kit. 
Crystalline formation was observed in well condition G4, 0.1 M sodium citrate pH 5.5, 
20% (w/v) PEG 4000 and 18% (v/v) iso-propanol. The crystals were observed in well 
1 and well 2 with protein to reservoir ratio of 2:1 and 1:1 respectively. UV 
illumination on the wells resulted in the crystals 'shining' against the dark background 
(Fig 18). This reduced the possibility of my crystals being a salt as only tryptophan 
residues in protein emit light at high intensity upon UV absorption. The crystals were 







Figure 18. Visible light and UV-illumination images of ∆31-FTO-complex 
crystals. FTO crystals were small and highly nucleated. FTO crystals shone 
brightly against the background under UV-illumination.  
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Crystal optimisation: Grid screening of crystallisation space around the hit condition 
was carried out using hanging drop. Grid screening allowed two-dimensional 
exploration of crystallisation space. The pH of the buffer and percentage of 
precipitant were subjected to initial screening. Further investigation revealed pH does 
not affect the size and nucleation of the crystals. However, lowering the percentage of 
precipitant resulted in better nucleation (lesser crystal formation). Finally, changing 
the type of precipitant from 10% (w/v) PEG 4000 to 10% (w/v) PEG 3350 resulted in 
slightly bigger crystals which could be picked. The crystals were observed to adopt a 
cubic form of morphology (Fig. 19A). At this point, crystals were picked, cryo-
protected and could diffract up to 3.5 Å at SLS. The diffraction data could also be 
processed by XDS and solved by molecular replacement using phases derived from 
previously solved structure (PDB ID: 4IE5). However, bigger crystals were needed to 






Figure 19. ∆31-FTO crystal hit optimisation. A. Small and highly nucleated 
crystals that grew in 100 mM sodium citrate, pH 5.6, 10% PEG 4000, 15% iso-
propanol. B. Large cuboid crystals that grew in 100 mM sodium citrate, pH 5.6, 
10% PEG 3350, 15% t-butanol. 
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During the period of optimising the condition of FTO, a paper on various co-crystal 
structures of FTO was published. 4% (v/v) t-butanol was used as additive in place of 
iso-propanol [247]. This prompted us to screen various organic\ solvents with similar 
structure as iso-propanol. Gratifyingly, at around 12% (v/v) t-butanol, crystals of FTO 
grew to a much bigger and pick-able size within a week (Fig. 19B). These FTO 
crystals were able to diffract up to 2.7 to 3.0 Å at SLS which allowed us to observe 
small molecular inhibitors binding to FTO at atomic resolution. It is noteworthy that 
no additive was used for crystallisation condition of the first reported crystal structure 
of FTO [91]. We were unable to reproduce crystallisation of FTO supplemented with 
4% (v/v) t-butanol as reported [247].  
3.6 Structural determination 
Diffraction experiments were conducted in Swiss Light Source (SLS) at Paul Scherrer 
Institute (PSI) (Switzerland). Most of the crystals diffracted up to ~5 to 6 Å. In 
addition, some crystals which were able to diffract beyond 3 Å do not have visible 
electron density for the target ligands after data processing by XDS and structure 
solved by MR. We managed to collect three full datasets for FTO co-crystals which 
showed unambiguous occupancy of our inhibitors at atomic resolution. Template 
(PDB ID: 4IE5) was used to obtain the phases for MR [247]. The crystals crystallised 
as a monomer with one molecule per asymmetrical unit, adopted a trigonal crystal 
system with a H3 space group. Finally, the structures were refined with nickel (II) and 




PDB ID 4CXW 4CXX 4CXY 
Data collection    
Resolution (Å) 50.00-3.05 49.18-2.71 50.00-2.60 
Resolution# (Å) 3.10-3.05 2.76-2.71 2.65-2.60 
Space group R3 R3 R3 
Cell dimension    
a, b, c (Å) 141.6, 141.6, 83.8 
 
140.7, 140.7, 83.3 
 
141.9, 141.9, 83.8 
 α°, β°, γ° 
 
90, 90, 120 
 
90, 90, 120 
 
90, 90, 120 

























































   
Bond length (Å) 0.011 0.011 0.010 
Bind angle (°) 1.385 1.315 1.398 






Table 4. X-ray diffraction data and refinement statistics. #Values in parentheses 
are for the highest resolution shell. 
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3.7 Binding mode of inhibitors with FTO  
As expected, the FTO in complex with various inhibitors contained two domains, the 
N-terminal DSBH domain and the C-terminal helical bundles. Overall, they did not 
display any significant difference compared to the previously published structures 
[91, 247].  
In the 2OG binding site of FTO, Ni(II) which substituted in place of natural co-factor 
Fe(II), was observed to coordinate to three highly conserved residues (His231, 
Asp233 and His307), which form the catalytic triad characteristic of AlkB oxygenases 
(Fig. 20 -23). A water molecule coordinating to Ni(II) was consistently observed trans 
to His231. In addition, the Fo-Fc omit map depicted unambiguous occupancy of the 
inhibitors could be observed in the 2OG and nucleotide binding sites of FTO. PDB 
coordinates of the inhibitors generated by PRODRG server were able to fit snugly 
into the Fo-Fc omit map and refined for analysis of the mechanism of inhibition. 
These inhibitors did not induce any noticeable conformational change to the residues 
lining the FTO active site. 
Inhibitor 12 (PDB ID 4CXW): The Fo-Fc omit map demostrated the umambiguous 
occupancy of inhibitor 12 in the catalytic domain of FTO (Fig. 20). The inhibitor 12 
consists of two components, namely the 2OG-binding component that resembles 
fumarate and the substrate binding component that occupies the substrate binding site. 
The two components are tethered by a hydrazide functional group. The acylhdryazine 
group of 12 forms a bidentate coordination to Ni(II), completing a hexadentate 
coordination around Ni(II). C-4 carbonyl oxygen of 12 binds to Ni(II) trans (2.1 Å) to 
Asp233 and hydrazine nitrogen of 12 binds to Ni(II) trans (2.1 Å) to His307. The 
carboxylate oxygens from C-1 of 12 form salt bridges to Arg316 (3.0 Å and 3.1 Å). In 
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addition, these carboxylate oxygens form hydrogen bonding interactions with nearby 
hydroxyl group of Tyr295 (2.7 Å) and Ser318 (2.9 Å). Superimposition of 4CXW 
with 3LFM (FTO-m3T-NOG) complex revealed that NOG and the 2OG binding 
component of 12 overlay very well, demonstrating similar NOG/2OG contacts in both 
structures (Fig. 21).  
The 4-benzyl pyridine that makes up the substrate binding component of 12 occupies 
the nucleotide substrate binding site of FTO (Fig. 21). The 4-benzyl pyridine and the 
nucleobase of m3T occupy almost similar position (Fig. 21). They are positioned 
almost parallel to His231 forming a π-π stacking interaction. They are also positioned 
in an almost parallel fashion as Tyr108, similarly forming a π-π stacking interaction, 
albeit weaker compared to the former (His231). The 4-benzyl pyridine aligns well 
with m3T of 3LFM. The pyridyl nitrogen is positioned similarly to O4-m3T, which 
points away from the substrate entrance forming a hydrogen bonding interaction with 
the amide oxygen of Glu234 (2.9 Å). The pyridyl carbonyl oxygen of 12 forms a 
hydrogen bonding interaction with Arg322 (2.8 Å). This interaction is absent in the 
corresponding m3T. The 4-benzyl substituent of 12 extend toward the opening of the 
catalytic domain, occupying a similar position with the ribose sugar ring of m3T. 
They participate in a similar hydrophobic interaction with nearby residues Leu109 


















Figure 20. Crystal structure of FTO (white sticks) bound to 12 (orange sticks). 
The diagram on left shows the detailed interaction map of 12 with its surrounding 
residues. The diagram on the right shows the Fo-Fc omit map with 12 fitted into it.  
Figure 21. Crystal structure of m3T and NOG superposed with 12 (orange 
sticks). The 4-benzyl pyridine and the nucleobase of m3T occupy almost similar 
position. The 2OG-binding component of 12 aligns with NOG very well. 
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Inhibitor 16 (PDB ID 4CXX): The inhibitor 16 is an analog of 12, with an additional 
t-butyl group at the para position of 4-benzyl substituent of 12 (Fig. 22). The t-butyl 
group points toward the opening of FTO catalytic domain and is observed to make 











Figure 22. Crystal structure of FTO (white sticks) bound to 16 (blue sticks). 
The diagram on left shows the detailed interaction map of 16 with its surrounding 
residues. The diagram on the right shows the Fo-Fc omit map with 16 fitted into it. 
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Inhibitor 21 (PDB ID 4CXY): Inhibitor 21 is an analogue of 12, with absence of the 
4-benzyl substituent. 21 makes similar interactions as 12 (Fig. 23). Interestingly, an 
intense Fo-Fc omit map that is characteristic of metal (electron dense) was observed 
during the refinement of FTO-21 crystal structure. The metal was presumed to be 
Ni(II) as it was present at high concentration during crystallisation. This observation 
was absent for inhibitor 12 and 16, where the similar position was occupied by a 
water molecule. The nickel makes an interaction with the hydrazine nitrogen (2.9 Å) 
and oxygen (3.6 Å, nearer to the pyridien ring) that are not involved in the chelation 







Figure 23. Crystal structure of FTO (white sticks) bound to 21 (green sticks). 
The diagram on left shows the detailed interaction map of 21 with its surrounding 
residues. The diagram on the right shows the Fo-Fc omit map with 21 fitted into it. 
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3.8 Energy minimisation of FTO and ALKBH5 oligonucleotide complex 
In silico modeling experiments were performed to understand if there are any 
conformational changes between enzyme inhibitor and substrate complexes. Not 
much conformational change was observed after the modelling experiments, and only 
slight rotation of Arg96 and Tyr108 in FTO has taken place (Fig. 24A). In ALKBH5, 
a flip of Tyr141 (indicated by red arrow) was observed when oligonucleotide was 
fitted into the domain (Fig. 24B). These residues are known to either make 
electrostatic interaction with phosphate backbone of oligonucleotide or form π-π 
stacking interaction with the nucleobases. Presumably, their conformational changes 
take place to make interaction with the oligonucleotide. FTO and ALKBH5 are most 
likely not to make a large conformation change upon substrate binding reflected by 
their inherent low affinity toward oligonucleotides. However, more experimental data 
such as structural studies are required to test this hypothesis. 
 
Figure 24. Energy minimised models. A. Unliganded FTO (white) superimposed 
with energy minimised FTO-GG(m6A)CU complex (orange) (RMSD of all atoms 
= 0.6 Å) . B. Unliganded ALKBH5 (white) superimposed with energy minimised 
ALKBH5- GG(m6A)CU complex (pink) (RMSD of all atoms = 0.3 Å). The C-
terminal helical bundle of FTO and oligonucleotides were removed for clarity. A 




3.9 Characterisation of RNA oligonucleotide substrates 
Several purposefully designed RNA oligonucleotides (RNA-1 to 6) were investigated 
in order to shed light on the substrate preference of FTO (Fig. 25). The 
oligonucleotides RNA-2, RNA-4 and RNA-6 potentially could adopt different 
conformations, consequently their influence on preferential demethylation of FTO and 
ALKBH5 was investigated.  The two conformations are: 
1) Duplex conformation by intermolecular base pairing. 
2) Hairpin conformation by intramolecular base pairing. 
 
 
Figure 25. RNA sequences. Various standard markers were designed to aid in our 
investigation. Marker-1 is a single-strand RNA standard. Marker-2 and 3 are 
duplex standard. Marker-4 is a hairpin standard. RNA-1 to 6 are purposefully 
designed RNA oligonucleotides that we used for our studies. 
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3.9.1 CD spectroscopy 
Unmethylated RNA-1 (rCCGGAAUUCCGG) and methylated RNA-2 
(rCCGG(m6A)AUUCCGG) did not show significant conformation differences in 
their CD profiles. CD profiles of both oligonucleotides superimposed very well (Fig. 
26A). Both exhibited a strong positive UV absorption band at 264 nm and a negative 
absorption band at the region around 212 nm, characteristic of A-form double helical 
structure [266]. RNA 1 and 2 are believed to adopt a fully base-paired duplex 
structure based on the CD profiles.  
Unmethylated RNA-3 (rCGCGAAUUCGCG) and methylated RNA-4 
(rCGCG(m6A)AUUCGCG) showed significant conformation differences in their CD 
profiles (Fig. 26B). RNA-3 has very similar CD profile with RNA 1 and 2. RNA-3  
has a strong positive UV absorption peak at ~264 nm and a negative absorption peak 
at ~212 nm, characteristic of A-form double helical structure. However, RNA-4 has a 
distinctly different CD profile compared to its unmethylated analog RNA-3. The 
strong absorption peak was shifted from ~264 nm to ~280 nm. The CD profile of 
RNA-4 still showed a negative absorption peak at ~212 nm. Based on the CD profile, 
RNA-3 is believed to be fully base paired. However, RNA-4 is believed to have a 
major change in its conformation due to introduction of m6A. It was later revealed 
that RNA-4 existed as a mixture of duplex and hairpin conformation. The mixture of 
conformers resulted in the change of CD profile. Supported by other orthogonal 
experiments UV-melting experiments, Van't Hoff analyses and non-denaturing PAGE 
analyses, a mixture of conformers in RNA-4 were indeed present. 
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Like RNA-3 and 4, unmethylated RNA-5 (rCGCGUAUACGCG) and methylated 
RNA-6 (rCGCGU(m6A)UACGCG) showed significant conformation differences in 
their CD profiles (Fig. 26C). RNA-5 has a similar CD profile compared with that of  
RNA-3, demonstrating a certain characteristic of A-form double helical structure. 
RNA-6 has a CD profile comparable to RNA-4, reflecting a mixture of duplex and 
hairpin conformation, in agreement with the results by other orthogonal experiments 











Figure 26. CD profiles of RNA oligonucleotides. A. RNA 1 and 2 showed similar 
CD profile. B. RNA 3 and 4 showed different CD profile, indicating different 
conformation between methylated and non-methylated oligonucleotides. C. RNA 5 
and 6 showed different CD profile, indicating different conformation between 
methylated and non-methylated oligonucleotides. 
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3.9.2 Non-denaturing PAGE analysis 
Non-denaturing PAGE was used to visualise the presence of different conformations 
of RNA oligonucleotides, given its structure/conformation directly linking to shift. As 
shown in Fig. 27, Marker-1 (rGCGG(m6A)CUCCAGAUG) served as a single-
stranded marker, and Marker-2, as a duplex conformation marker, is made up by 
annealing the same concentration of Marker-1 and its complementary strand 
(rCAUCUGGAGUCCGC). Finally, Marker-4 (rGCGG(m6A)CUCCACCGC) served 
as a hairpin marker. In a typical non-denaturing PAGE, Marker-2 has the lowest 
mobility, whereas Marker-4 has the highest mobility among the three markers. All 
the standard markers have different rate of migration, which could be deciphered 
unambiguously (Fig. 27). 
Non-denaturing PAGE analysis of RNA 1 to 6 at three concentrations (2.5, 5 and 10 
μM) revealed the presence duplexes and hairpins, while compared with the standard 
markers. RNA-1 to 3 and 5 have migration pattern similar to duplex standard marker. 
This observation is consistent with the CD profiles of RNA-1 to 3 and 5 where they 
displayed clear A-form duplex structure. 
However, RNA-4 and 6 were demonstrated to form hairpin. Furthermore, high 
proportion of hairpin formation could be observed at relatively low concentration of 
RNA-4 and 6 (2.5 μM and 5 μM). The hairpin band was inherently faint compared to 
the bands of duplex or single- strand at similar concentration. This is probably due to 
the current usage of SYBR® Gold Nucleic Acid Gel Stain not optimised for hairpin 
visualisation. Taking this into consideration, the percentage population of hairpin for 
RNA-4 and 6 was at least 20% and 35% at 5 μM and 2.5 μM, respectively. The 
presence of both hairpin and duplex could be directly interpreted from the CD profiles 
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of RNA-4 and 6. Hence, we could infer that the hairpin formation is due to the 











Figure 27. Native PAGE and in vitro demethylation of different conformations of 
RNA. FTO and ALKBH5 preferentially demethylate single strand and hairpin RNA 
oligonucleotides. (Demethylation data was from the lab of Dr Esther Woon.) 
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3.10 Characterisation of FTO and substrate interaction  
Both m6A demethylases, FTO and ALKBH5 were noted to preferentially demethylate 
marker-1 and 4. However, there was no notable amount of demethylation activity 
with marker-2 (based on the result from the lab of Dr Esther Woon).  
3.10.1 Biotin-EMSA 
The lack of demethylation activity of FTO and ALKBH5 toward duplex could be 
rationalised by the lack of binding affinity. There was no detectable binding of biotin-
labelled marker-3 to FTO and ALKBH5. When the proteins were incubated even at 
1250 molar excess with respect 3'-biotinylated marker-3 (4 nM), no retardation was 
observed (Fig. 28A and B).  
On the contrary, demethylation activity of FTO and ALKBH5 towards single-
stranded marker-1 can be rationalised by the presence of binding affinity (Fig. 28A 
and B). Dose-dependent retardation of 3'-biotinylated marker-1 could be observed in 
the biotin-EMSA experiment. Significant retardation could be observed when FTO 
and ALKBH5 was incubated at 500 molar excess with respect to 4 nM of 3'-
biotinylated marker-1. Nevertheless, the affinity of FTO and ALKBH5 towards 
single-stranded oligonucleotide is considered to be weak based on the biotin-EMSA 
experiments.  
No apparent binding of FTO and ALKBH5 towards hairpin marker-4 was observed 
despite the ability of FTO and ALKBH5 to demethylate a hairpin (Fig. 28C). This 
may be due to 3'-biotin affecting the interaction of FTO and ALKBH5. Nevertheless, 










Figure 28. Biotin-EMSA of FTO and ALKBH5 with 3'-biotin labelled 
oligonucleotides. A. Biotin-EMSA of FTO with 3'-biotinylated marker-1 and 3. B. 
Biotin-EMSA of ALKBH5 with 3'-biotinylated marker-1 and 3. C. Biotin-EMSA 
of FTO and ALKBH5 with 3'-biotinylated marker-4. 
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3.10.2 MST (label-free) assay 
MST allows an accurate determination of binding affinity of proteins to their binding 
partners (without labels) through quantification of dissociation constant (KD). The 
quantification of the affinity between proteins and their partners is based on the 
population of proteins at equilibrium upon thermophoresis. The population of the 
proteins are quantified by the intrinsic fluorescence of the fluorophore, tryptophan 
residues. As such, protein without tryptophan is unable to be quantified via MST. In 
addition, binding partners of proteins should not have or possess at most a third of 
protein fluorescence such that interference of the protein fluorescence measurement is 
kept to the minimal. 
Gratifyingly, the intrinsic fluorescence of marker-1 (single-strand) and marker-4 
(hairpin) was less than three times of the fluorescence of FTO (100 nM) and 
ALKBH5 (500 nM). This allowed us to determine the binding affinity of marker-1 
and marker-4 for the proteins (Fig. 29). As expected, FTO and ALKBH5 has a weak 
binding affinity towards marker-1 (KD (FTO) ~97.1 μM; KD (ALKBH5) ~52.9 μM) 
and marker-4 (KD (FTO) ~91.3 μM; KD (ALKBH5) ~75.3 μM). The binding data was 






Figure 29. MST assay to quantify binding affinity of FTO and ALKBH5 to 
marker-1 and 4. FTO and ALKBH5 have weak binding to marker-1 and 4. A. 
MST assay of FTO with marker-1. B. MST assay of FTO with marker-4. C. 






















4.1 Structural basis of FTO-substrate affinity  
4.1.1 FTO and oligonucleotides 
Most of the AlkB oxygenases in this thesis were able to selectively demethylate N-
methylated nucleobases of single-stranded or duplex oligonucleotides, while 
crystallographic data aided towards a better understanding of the recognition between 
AlkB oxygenases and oligonucleotides. Sample preparation of highly concentrated, 
pure and homogenous AlkB oxygenase-oligonucleotide complexes is a prerequisite to 
crystallisation trial, which proved to be challenging. Prior to the commencement of 
our structural and mechanistic study of FTO, different groups of scientists had tried to 
crystallise E. coli AlkB, an FTO homolog, in complex with DNA. Among which, Dr 
Chuan He stated that the crystallisation of E. coli AlkB is almost impossible. E. coli 
AlkB has inherently weak affinity for DNA with and without alkylation damage [217]. 
In addition, the inability of AlkB to recognise a specific sequence of nucleotides make 
it increasingly difficult to form a homogenous complex. Consequently, reviewed 
earlier in this thesis, Dr. Chuan He employed a disulphide cross-linking strategy to 
trap the oligonucleotides in a fixed conformation in AlkB and ALKBH2. The crystal 
structures of AlkB and ALKBH2 with covalently trapped oligonucleotides 
represented the only known type of AlkB-DNA complexes thus far. This provided us 
with vital information of how FTO could possibly interact with its nucleotide 
substrates.     
FTO-ssRNA complex: Prompted by the ability of recombinant FTO to demethylate 
some oligonucleotide substrates in vitro, we attempted to interrogate the structure of 
FTO complexed to m3T-containing ssDNA and m6A-containing RNA 
oligonucleotides. Although crystallisation trials yielded isomorphous crystals that 
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diffracted up to 3 Å, there was no sign of the occupancy of oligonucleotides upon 
solving the crystal structures. DSF analysis showed weak binding (Tm shift ~3°C) of 
FTO to various methylated or unmodified oligonucleotides. This observation was 
supported by biotin-EMSA, in which over a thousand fold excess of FTO was 
required for a small amount of retardation to be observed. It was further corroborated 
by MST assay, where the binding affinity was quantified (KD (FTO) ~97.1 μM), 
indicating rather weak binding. Hence, these data suggested that the interaction 
between FTO and oligonucleotides is inherently weak.  
DSF was performed on some recombinant AlkB N-demethylases and the binding data 
indicated that AlkB oxygenases also interact weakly with the oligonucleotides (Table 
2). Further investigations on m6A demethylase ALKBH5 also showed weak binding 
via biotin-EMSA and MST assay (Fig. 28 and 29).  
Observation from the crystal structure of FTO revealed various basic and aromatic 
residues present in the NRL1, NRL2 and L1 loop that were reasonably speculated to 
interact with oligonucleotides. To further rationalise the weak binding between FTO 
and its substrate oligonucleotide, a modelling study of a m6A-containing RNA 
docked into the domain and subjected to energy minimisation was carried out. Ideally, 
if the binding between the two entities is favourable, conformational changes of 
various protein residues to interact with the phosphate backbone or nucleobases 
should be observed. However, minimal conformational change was observed. Similar 
observations were noticed for ALKBH2. When oligonucleotide was fitted into the 
domain of ALKBH5, there was a flip of Tyr141, which presumably to make an 
interaction with a nucleobase (Fig. 24B). 
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TET as a close family to AlkB: TET1-3 belong to another 2OG oxygenase family that 
is known to perform oxidation on methylated nucleotides (5mC, 5hmC and 5fC) 
through a similar mechanism to that of AlkB oxygenases (Fig. 1). Superimposition of 
the DSBH domains of TET2 with E.coli AlkB and FTO showed highly aligned 
secondary structures. However, TET2 has much higher affinity for oligonucleotides, 
and the crystal structure of TET2:DNA complex (PDB ID 5DEU) was solved without 
cross-linking strategy. Although with highly similar DSBH domains, there were stark 
differences in the loops that preceded and in between various E-strands of the DSBH 
domain in how they interact with the oligonucleotides. The loops of TET2 potentially 
contributed to the high oligonucleotide affinity. 
Together with Dr. Chuan He’s and our observations, we could conclude that AlkB 
family of N-demethylases only weakly bind to their substrates. Strong interaction of 
proteins with their substrate oligonucleotides would hinder the folding or binding of 
important factors onto the DNA or RNA. It is reasonable to suggest that AlkB 
proteins are meant to perform the covalent modifications on the oligonucleotides and 








4.1.2 FTO and nucleotides 
DSF and in vitro demethylation assays have indicated that recombinant FTO has 
stronger binding (Tm shift = 12.1°C) and demethylation profile (~20% conversion) for 
m3T compared to other recombinant AlkB oxygenases. Structural analysis of FTO 
complexed with m3T and NOG (PDB ID 3LFM) with other AlkB oxygenases 
structures could perhaps rationalize the above difference in affinity.  
We superimposed FTO with crystal structures of AlkB (PDB ID 3I3M), ALKBH2 
(PDB ID 3BUC), ALKBH3 (PDB ID 2IUW), and ALKBH5 (PDB ID 4NJ4) (Fig. 30). 
Residues lining the AlkB oxygenases’ functional domains were in the active 
conformation, complexed to co-factors and some with substrates that stabilised the 
DSBH domains. Nucleotide binding sites of the AlkB oxygenases compared were 
largely similar to FTO (Fig. 30). The nucleotide binding sites were lined with some 
highly conserved residues or substituted for structurally equivalent residues that were 
able to make meaningful interactions with m3T. The loss of binding affinity towards 
m3T in other AlkB oxygenases is highly possible due to the substitution of residues 
that involves in strong interaction with m3T. 
Substitution of Arg96FTO by Met61AlkB and Gln112ALKBH2 led to the loss of interaction 
and decreased efficiency of binding with O2-m3T, respectively (Fig. 30A and D). The 
interaction was further weakened, where amide backbones of Asp132AlkB and 
Asp174ALKBH2 were positioned at a distance of ~4.6 Å (average), thus unable to make 
efficient contact with O4-m3T in comparison to the corresponding Glu234FTO. 
Crucially, corresponding Tyr108FTO residues in ALKBH3 and ALKBH5 were unable 
to make stabilising S-S interaction with the nucleobase of m3T (Fig. 30B and C). 
Both Tyr143ALKBH3 and Tyr139ALKBH5 were positioned perpendicular to the 
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nucleobase of m3T, weakening the S-S interaction. Nevertheless, this rationalisation 
might be inaccurate as the crystal structures of ALKBH3 and ALKBH5 used for 
comparison were not solved with substrate lining the nucleotide binding pocket. 
Potentially, Tyr143ALKBH3 and Tyr139ALKBH5 could ‘switch’ and form a S-S 
interaction with the nucleobase of their preferred substrate. Further analysis revealed 
that the amide backbones of Tyr143ALKBH3 and Tyr139ALKBH5 were unable to ‘switch’ 
to form a meaningful S-S interaction without interrupting and destabilising the 
alignment of nearby CD backbone. In addition, energy minimisation of ALKBH5 with 
oligonucleotide revealed no significant conformational change of Tyr139ALKBH5. The 
way CD backbone near Tyr139ALKBH5 was positioned prevented such S-S interaction. 










Figure 30. Comparison of various AlkB oxygenases substrate binding sites 
with FTO. A. Comparison of ALKBH2 with FTO. B. Comparison of ALKBH3 
with FTO. C. Comparison of ALKBH5 with FTO. D. Comparison of AlkB with 
FTO. 
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4.2 Strategy for selective inhibitor design 
No report of potent and selective inhibitor for AlkB oxygenases was present 
previously. Rhein was reported to inhibit FTO in vitro and in cells, however, rhein 
also inhibits other AlkB oxygenases [207, 246]. The inhibitors available (NOG and 
2,4-PDCA) were generic and they bind indiscriminately to the 2OG-binding site of 
AlkB oxygenases, chelating to the Fe(II) co-factor. Analysis of the substrate binding 
sites of AlkB oxygenases crystal structures revealed important differences that 
accounted for their substrate selectivity. We took advantage of these structural 
differences for the design of our inhibitors for FTO. Given that the substrate binding 
site could be exploited for selective inhibition, designing an inhibitor that could 
simultaneously occupy the 2OG and substrate binding sites of FTO would fuel its 
potency and selectivity (Fig. 31). The ‘two-component’ inhibitor was made up of a 
‘2OG-binding component’ and a ‘substrate-binding component’ tethered together. 
Among all the inhibitors synthesised from the lab of Dr Esther Woon, 12 gave the 





Figure 31. The ‘two-component’ inhibitor. The inhibitor is designed to 
simultaneously occupy the 2OG-binding and substrate-binding site.  
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4.3 Analysis of the binding mode of inhibitor 12 
Kinetic studies were performed in Dr Esther Woon’s lab. The analyses showed that 12 
had a mixed mode of inhibition with m3T. Thus, 12 could bind to a free FTO and 
compete with FTO-m3T. Indeed, 12 demonstrated a competitive inhibition towards 
co-substrate 2OG. This made sense as 12 occupied the same site as 2OG. 
A series of analogues of 12 were synthesised and tested for inhibitory activities 
against FTO and other AlkB oxygenases by DSF and HPLC in vitro demethylation 
assay (Table 3). 12 showed weak inhibition towards AlkB (IC50 = 33.5 PM; Tm = 
4.5°C) and ALKBH2 (IC50 = 25.9 PM; Tm = 4.9°C), recpectively. However, 12 still 
maintained over more than 20 fold potency towards FTO (IC50 = 0.81 PM; Tm = 
11.2°C) compared to AlkB and ALKBH2. Remarkably, 12 was more than 100 fold 
selective toward FTO compared to ALKBH5 (IC50 = 108.1 PM; Tm = 2.7°C). 
ALKBH5 and FTO have m6A as their major natural substrate. This is important as 
the ability of 12 to selectively inhibit FTO made it a potential functional probe to 
understand the biological roles of FTO and ALKBH5 in m6A-mediated epigenetic. 
The benzyl group of 12 is most probably not crucial for its selectivity towards FTO. 
However, this could be seen in 21, with the benzyl substituent removed. Although 21 
inhibited FTO (IC50 = 11.8 PM; Tm = 7.4°C) to a lesser extent, it maintained at least a 
100 fold selectivity towards ALKBH3 (IC50 = 114.6 PM; Tm = 2.5°C). The benzyl 
group most likely contributed to the potency of 12 towards FTO via hydrophobic 
interactions. Crucially a complete elimination of selectivity was observed when the 
pyridyl nitrogen was moved from the meta to ortho position. The position of pyridyl 
nitrogen is most likely a key determinant for selectivity. In the crystal structure of 
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FTO complexed to 12, it showed that the position of the nitrogen is indeed important 



















4.4 Rationalisation of inhibitor 12 selectivity 
The selective mechanism of 12 was revealed when we compared the structure of 
FTO-12 complex with that of AlkB oxygenases. Inspection of the 2-OG binding sites 
of FTO and the AlkB oxygenases revealed some highly conserved residues. 
Particularly, the catalytic triad aligned very well across all the AlkB oxygenases (FTO, 
AlkB, ALKBH 2, 3 and 5) used for comparison. In addition, the arginine residues that 
form salt bridges to the carboxylate end of 12 were also conserved in all the AlkB 
oxygenases. Due to highly similar binding mechanism between the AlkB oxygenases 
and the 2OG-binding component of 12, it could be concluded that this component 
conferred potency but not selectivity to the binding. Potency of 12 towards FTO could 
also be explained through the expanded hydrogen bonding network where the 
carboxylate end of 12 interacts with Ser318FTO and Tyr295FTO. Corresponding 
residues in other AlkB oxygenases were substituted for residues that are less polar or 
unable to make direct contact due to unfavorable distance. 
The selectivity of 12 for FTO could be rationalised by aligning the substrate-binding 
sites of the crystal structures of AlkB oxygenases (Fig. 32). There are some distinct 
differences in the residues lining the substrate-binding site that weaken binding 
affinity of 12. The S-S interactions with the pyridyl ring of 12 were severely 
weakened for Tyr143ALKBH3 and Tyr139ALKBH5 as the positions of how the tyrosines 
were placed discouraged stacking interactions observed in Tyr109FTO, Trp169AlkB and 
Phe124ALKBH2 (Fig. 32 A and B). 
It is worth noting that the position of the nitrogen in the pyridyl ring played a 
significant role in determining the potency and selectivity of 12. The pyridyl nitrogen 
of 12 made a hydrogen bonding with amide backbone of Glu234FTO, while the 
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corresponding residues of Glu234FTO in other AlkB oxygenases, Asp135AlkB, 
Asp174ALKBH2, Asp194ALKBH3 and Pro207ALKBH5 were positioned too far away from 
the pyridyl nitrogen to make any interactions (Fig. 32). That accounted for the 
severely diminished or abolished affinity of 12 for other AlkB oxygenases. In addition, 
the crystal structure of FTO-12 complex offered an explanation regarding the loss of 
potency of 23 (pyridyl nitrogen was moved from the meta to ortho position) towards 
FTO.  
Prior to the development of inhibitor 12, there were no potent and selective binders to 
FTO [246, 247]. Notably, natural product rhein bind promiscuously to FTO and other 
AlkB enzymes inhibiting their catalytic activities (Fig. 33A). Overlying both crystal 
structures of FTO complexed to inhibitor 12 and rhein revealed both inhibitors 
occupied similar nucleotide binding region and made similar interactions with the 
surrounding residues (Fig. 33A). However, rhein lacks the pyridine nitrogen that 
offered 12 the selectivity toward FTO. Following the report of inhibitor 12, there were 
two notable reports of selective inhibitors for FTO [249, 251]. The reported inhibitors 
(meclofanamic acid and a fluorescein derivatised compound) revealed a novel binding 
mechanism (Fig. 33A & B). Both inhibitors contained a phenyl ring that interacted 
hydrophobically with Ile85, Leu90 and Pro93 of the NRL1 situated near the entrance 
of FTO catalytic domain. NRL1 is longer and extended in FTO. On the other hand, 
the much shorter NRL1 in ALKBH5 is unable to make similar interaction (Fig. 33D). 









Figure 32. Rationalisation of selectivity of 12 by superimposing available crystal 
structures.  Particularly, 12 was unable to form good contact with residues of other 
AlkB oxygenases corresponding to Glu234FTO A. Superimposition of FTO and 
AlkB . B. Superimposition of FTO and ALKBH2. C. Superimposition of FTO and 












Figure 33. Binding modes of different inhibitors.  A. Overlay of 12 with natural 
product rhein. B. Overlay of 12 with meclofanamic acid (MA). C. Structural 
comparison of NRL1 of FTO (white) and ALKBH5 (salmon). D. Overlay of 12 with 
fluorescein derivatised inhibitor (Fl). 
 105 
4.5 Potential of 12 as functional probe 
The compound 25, an ethyl ester derivative of 12, was able to penetrate the cell 
membrane better than 12, and subsequently, hydrolysed to 12 in the cells. Preliminary 
studies on 25 showed that it is non-toxic to cells up to 100 PM, and is able to inhibit 
the demethylation activity of FTO.  
There are established criterion that classify compounds as drug-like if they fall largely 
within an acceptable quantified categories. On the other hand, classifying compounds 
as probe-like is a relatively new concept. There are various literatures and 
commentaries that suggested what constitute to be good probes [267-269]. It is 
important to note that drugs and probes may have overlapping profiles, but they serve 
distinct purposes and need not be a subset of each other. The Structural Genomic 
Consortium (SGC) classifies a probe that possesses good in vitro potency (less than 
100 nM), high selectivity within a family of structurally related proteins (more than 
30 fold) and a good on-target in cells (at less than 1 PM) [267-269].  
12 showed promising results in in vitro studies and preliminary cellular profiling. 
However, further verification is required with regards to whether FTO is indeed 
specifically targeted and whether there is minimal or insignificant off-target effects in 
cells. Only then it could be possible to perturb and study the mechanistic roles FTO 






4.6 M6A can influence conformations of oligonucleotides 
M6A is the most common epigenetic modification found within highly conserved 
consensus sequences (DRACH; where D = A, G or U; R = G or A and H = A, C or U) 
in eukaryotic mRNA and is able to dictate the fate of mRNA. Reviewed earlier in this 
thesis, m6A did not prevent Watson-Crick base pairing, however it destabilised the 
base pairing by 0.5-1.7 kcal/mol, depending on sequence context. Various secondary 
structures are adopted by mRNA and there have been reports of m6A modifications 
that influence secondary structures of RNA oligonucleotides [109, 131, 270]. Given 
that FTO and ALKBH5 are able to recognise and demethylate their major substrate, 
m6A, it is of significant interest to know whether they are able to affect the change of 
RNA secondary structures upon demethylation. 
Several RNA oligonucleotides were designed to adopt duplex or hairpin conformation, 
involving Watson-Crick base pairing. As shown in chapter 3.9, not all m6A-
containing RNA oligonucleotides were able to elicit a change in the secondary 
structures. In the RNA oligonucleotides studied (RNA-2, 4 and 6), despite having the 
same base composition, two bases in the immediate proximity to the m6A 
modification could provoke a change in the overall conformation. Particularly, this 
becomes even evident when the concentration of oligonucleotides (RNA-2, 4 and 6) 
was below 5 PM. Observations of the behavior of these methylated oligonucleotides 
were confirmed by various experimental methods such as CD and non-denaturing 
PAGE, as described in chapter 3.9. Potentially, if FTO and ALKBH5 is able to 




4.7 M6A-induced RNA conformational change influences substrate specificity of 
FTO 
Given that m6A was practically found within a set of consensus sequence (DRACH), 
we asked how the consensus sequence is important for FTO and ALKBH5 
demethylation. HPLC-based in vitro demethylation on various DNA and RNA 
oligonucleotides containing m6A showed that the consensus sequence is not crucial 
for demethylation [132]. However, a minimal of four nucleotides is needed for m6A 
demethylation to occur for FTO and ALKBH5 (Table 5). It is noteworthy to mention 
that FTO could demethylate a single m3T nucleotide efficiently and not m6A [132, 
245]. On the other hand, such consensus sequence is crucial for other m6A 'writer' 
and 'reader' proteins, for instance, METTL3 and YTHDF2, where the consensus 
sequence motifs are crucial for recognition and effect of functions [85, 118, 120].  
The demethylation of FTO and ALKBH5 against highly similar sequences, RNA-2, 4 
and 6 were profiled (Fig. 27). The assay results in Fig. 27 showed that the 
demethylases preferred to catalyse RNA-4 and 6 at 5 PM and below. However no 
activity was observed for RNA-2. Notably, for RNA-4 and 6 at 5 PM, substantial 
hairpin conformation was observed but not for RNA-2. This suggested the 
demethylases preferentially demethylate certain m6A-induced conformation, hairpin 
in this context. When RNA-4 and 6 were at 10 PM, both existed as duplexes and no 
demethylation was observed. Upon demethylation, RNA-4 and 6 became RNA-3 and 
5, respectively. RNA-3 and 5 are duplexes and it could be speculated that in vivo, this 
drastic conformation change might possibly deter binding of certain regulatory 
proteins, thus affecting downstream biological events. However, more in vivo 
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investigations are required to prove that FTO and ALKBH5 are able to partake such 















 Table 5. Percentage demethylation of different sequences by FTO and 
ALKBH5. FTO and ALKBH5 displayed similar demethylation profile. 
Substantial demethylation observed with at least four-nucleotide long 
sequence. Consensus sequence is not essential for demethylation to occur. 
Recombinant proteins were purified in-house and demethylation studies were 
performed by Dr Esther Woon. 
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CHAPTER 5 

















Initially, m6A was thought to be a permanent mark in RNA. FTO gene is the first 
GWAS identified gene that has direct link to obesity, as well as its coding protein 
FTO is the first of the two m6A demethylases known so far that is able to remove the 
m6A modifications in RNA. The discovery of FTO therefore revealed that m6A 
modifications are dynamic and epigenetic regulation can occur in the layer of RNA 
transcripts. ALKBH5, the second m6A demethylase, was later discovered. Both FTO 
and ALKBH5 belong to AlkB 2OG oxygenases family of proteins and share highly 
similar domain architecture.  FTO and ALKBH5 have stark physiological functions, 
however, the mechanisms of how FTO and ALKBH5 affect their functions were 
largely unknown. 
It was of interest to develop a potent and cell-active probe that is selective for FTO to 
help us understand the mechanism of action of FTO in cells. This may set a good 
platform for therapeutic intervention for obesity in the long run. We cloned and 
purified various FTO and AlkB oxygenases and employed X-ray crystallography, 
DSF, in vitro demethylation assays and modelling studies to develope an inhibitor that 
is highly selective and active towards FTO. It was the first selective and active 
inhibitor for a member of human AlkB oxygenases family. We have shown that 
despite highly similar homologies among human AlkB members, the substrate-
binding site could be exploited for enhancing selectivity of inhibitor. 
RNA transcripts were known to adopt various conformations in vivo. Those 
conformations might play a part in various physiological functions, for instance, 
binding of regulation factors and translation regulation. We employed CD analyses, 
gel-shift technique, thermophoresis measurements and biochemical assays to show 
that, in principle, FTO can demethylate m6A-containing RNA in vitro and evoke a 
conformation change of the RNA oligonucleotide. With these in vitro data, we may 
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ask how the molecular mechanism of FTO in carrying out its physiological role 
entails conformational changes to RNA transcripts. 
Many have reported FTO and m6A in isolation. We understand the physiological 
effect of over and under expression of FTO. We are also beginning to understand  the 
physiological effect of the presence and absence of m6A in different parts of mRNA. 
However, we do not understand when and how FTO expression is regulated. We also 
do not know the mechanism of FTO and ALKBH5 recognition and discrimination of 
any mRNA transcripts given that both demethylases have distinct physiological roles. 
Arguably, understanding the mechanism behind the interplay between FTO and its 
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